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ABSTRACT 
The increased expression of fatty acid binding protein 4 (FABP4) and 5 (FABP5) play a 
crucial role in promoting tumorigenicity and metastasis of prostate cancer. FABP4 was 
suggested to be a therapeutic target for metastasis of prostate cancer. FABP5 was also 
proven to be a prognostic marker and potential treatment target. In contrast to numerous 
studies conducted to investigate the crucial role of FABP4 and FABP5 in prostate 
cancer, investigations on the possible involvement of other FABPs in the malignant 
progression of prostate cancer are rare. To find out whether any other FABP family 
proteins can also be used as diagnostic or prognostic markers for prostate cancer as 
FABP5, we measured the mRNA levels of 10 FABPs in benign and malignant prostate 
cell lines. Results showed that FABP4, FABP5, FABP6, FABP9 and FABP12 exhibited 
clearly higher levels in all tested malignant cell lines compared to their levels in the 
benign PNT-2 cells. Although, FABP4 and FABP5 have been associated with human 
prostate cancer as revealed in studies of our group and other groups, the finding of 
potential roles of FABP6, FABP9 and FABP12 have not been addressed. FABP12 is the 
most recently discovered member and no antibody was available for this candidate, thus 
FABP12 will be studied in a separate project of the group. Thereafter we assessed the 
expression status of FABP6 and FABP9 in both human prostate cell lines and tissues at 
the protein level. FABP6 protein was overexpressed only in 1 of the 5 malignant cell 
lines and its immunohistological staining intensities were not significantly different 
between the benign and the malignant prostate tissues. In contrast, FABP9 protein was 
highly expressed in highly malignant cell lines PC-3 and PC3-M, but its level in the 
benign PNT-2 and other malignant cell lines was not detectable. When analysed in an 
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archival set of human prostate tissues, immunohistological staining intensity for FABP9 
was significantly higher in carcinomas than in benign cases and the increase in FABP9 
was significantly correlated with reduced patient survival times. Moreover, the increased 
level of staining for FABP9 was significantly associated with the increased joint 
Gleason scores (GS) and androgen receptor index (AR). Suppression of FABP9 
expression in highly malignant PC3-M cells inhibited their invasive potential, but did 
not affect their growth rate, anchorage-independent growth and migration rate. Our 
results suggest that FABP9 is a valuable prognostic marker to predict the outcomes of 
prostate cancer patients, perhaps by playing an important role in prostate cancer cell 
invasion.
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1. Introduction  
1.1 Cancer incidence  
Cancer is the most serious health threat to human life (McGuire 2016). In 2012, it was 
estimated that 14.1 million new cancer cases were diagnosed in the world: 7.4 million in 
males (53%) and 6.7 million in females (47%) (Torre et al. 2015).  In 2013, there were 
about 350,000 new cancer cases were diagnosed in the UK, including 179,000 in males 
and 173,000 in females (CRUK 2013) (Figure 1. 1). Cancers of Lung, colon, breast and 
prostate account for 53% of all new diagnosed cases in the UK (CRUK 2013). About 
50% of all cases diagnosed during the period of 2011 to 2013 in the UK were in people 
aged 70 and over. The cancer incidence is more common in black and white males than 
in Asian males, whereas more common in white females than in black and Asian 
females.  Prostate cancer is the most common male cancer in the UK, accounting for 
26% of all new cancer cases in males (De Angelis et al. 2014; Torre et al. 2015).  
 
Figure 1.1 : Average number of new cases diagnosed for all cancers in the UK in 2013 
(CRUK 2013).  
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1.2  Epidemiology of prostate cancer 
1.2.1 Incidence 
Prostate cancer is the second most common cancer and the sixth leading cause of cancer 
death in the developed countries (CRUK 2013). In 2013, there were around 1.4 million 
cases of prostate cancer diagnosed and 293,000 deaths worldwide (Global Burden of 
Disease Cancer 2015). Prostate cancer is the most common male cancer in the UK, 
accounting for 26% of all new cases of cancer in males (CRUK 2016b) and 13% of all 
new cases in the UK (Ferlay J 2013) (Figure 1.2). In 2013, there were 47,300 new 
prostate cancer cases diagnosed in the UK. The incidence of prostate cancer increased 
through the entire 1980s and peaked in 1991 in United states  (Brawley 2012). Since 
1992, the serum prostate-specific-antigen (PSA) screen was used on a wide population 
and this marker helped early diagnosis of prostate cancer and thus contributed to 
improvements in subsequent 5-year survival rates (Adamson et al. 2003; Barry 2001; 
Moore et al. 2009). 
 
 
Figure 1. 2:  Male cancer incidence in the UK in 2013 (CRUK 2013). 
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1.2.2 Mortality 
In 2014, the number of patients died from prostate cancer was recorded as 11,300 in the 
UK, accounting for 7% of all cancer deaths as shown in Table 1.1. Prostate cancer is the 
4th most common cause of cancer death in the UK, accounting for 13% of all cancer 
deaths in males. Several separate studies have shown that mortality among patients with 
prostate cancer varies according to such factors as where they live (Papa et al. 2014; Yu 
et al. 2014), clinical management (Eggener et al. 2011; Shikanov et al. 2012) and marital 
status (Abdollah et al. 2011; Tyson et al. 2013).  
 Table 1.1: Prostate cancer mortality rate per 100,000 population in the UK, 2014 
(CRUK 2016b). 
 England Wales Scotland Northern 
Ireland 
UK 
Deaths 9,529 613 906 239 11,287 
Crude Rate 35.6 40.3 34.9 26.5 35.5 
Age-standardised (AS) Rate 48.2 50.2 46.7 42.4 48.1 
AS Rate – 95% lower 
confidence limit (LCL) 
47.2 46.2 43.7 37.0 47.2 
AS Rate – 95% upper 
confidence limit (UCL) 
49.1 54.2 49.8 47.8 49.0 
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1.2.3 Survival 
In England and Wales during 2010-2011, 94% of prostate cancer patients survived for 1-
year, then the survival rate fell to 85% for 5-years. Early detection via tests such as 
transurethral resection of the prostate (TURP) and PSA played a crucial role in this 
improved survival. One-year survival for prostate cancer has increased from 66% during 
1971-1972 to 94% during 2010-2011 in England and Wales (Figure 1.3) (CRUK 
2016b). Five-year survival for patients aged 15-49 was 91%, and this was increased to 
94% in patients aged 60-69-year-old; Five-year survival rate reached to its lowest point 
at 66% for patients aged 80-99 in England during 2009-2013. Moreover, stage of 
prostate cancer at diagnosis is strongly correlated with patient survival. For instance, 
2012 data in England show that 85% of patients diagnosed at stage IV survived for at 
least one year, versus 100% of patients diagnosed at stage I (ONS 2016b).    
 
Figure 1. 3: Prostate cancer relative survival rates, England and Wales 1971-2011 
(CRUK 2016b).  
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1.2.4 Factors affecting prostate cancer risk 
1.2.4.1 Age  
In the UK, around 54% of prostate cancer cases diagnosed are in people aged 70 and 
over; and only 1% are diagnosed in men under 50s. Also in the US, about 65% of all 
prostate cancer cases are diagnosed in patients aged 65 and over. Therefore, the risk 
increases with the increased age. When the age is over 65, the chance of developing 
prostate cancer is more common than any other cancer type in men (ONS 2016a).  
1.2.4.2 Family history 
There is an increased risk of prostate cancer in men with a history of prostate cancer in 
their family (Bruner et al. 2003; Johns & Houlston 2003). The risk of developing 
prostate cancer is 2.1-2.4 times higher in men whose father has or had the disease. The 
risk increases to 2.9-3.3 times in men whose brother has or had the disease (ACS 2016). 
Around 5-10% of prostate cancer cases are correlated with family history and hereditary 
factors. Also, it has been reported that the risk increase in men whose mothers has or had 
breast cancer by 19-24% (Chen et al. 2008; Hemminki & Chen 2005).   
1.2.4.3 Race 
The incidence and mortality rate of prostate cancer have been reported amongst different 
races worldwide. On the basis of the latest England data, it is clear that black men have 
higher risk of developing prostate cancer than their white counterparts (CDC 2016; 
Jones & Chinegwundoh 2014). African American patients develop more aggressive 
disease and have the highest rate of 275.3 per 100,000 which is 60% higher than the 
whites with a rate of 172.9 per 100,000 (Kumar 2005). Asians have the lowest incidence 
rate of prostate cancer; however, in recent years, some Asian countries have reported a 
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rapidly growing trend due to changes in lifestyle (Baade et al. 2013; Chen et al. 2014) 
(Table 1.2).    
Table 1.2: Incidence and mortality rate per 100,000 by race 2003–2007 (Brawley 2012).  
Race/ethnicity Incidence Mortality 
All races 156.0 24.7 
White            149.5 22.8 
Black 233.8 54.2 
Asian/Pacific Islander 88.3 10.6 
American Indian/Alaskan Native 75.3 20.0 
Hispanic 107.4 18.8 
 
1.2.4.4 Other cancers 
Previous studies have shown that urological carcinomas increase the risk of prostate 
cancer. For instance, renal (Liu, Hemminki & Sundquist 2011; Neuzillet, Lechevallier & 
Coulange 2007) and bladder (Kellen et al. 2007; Lehnert et al. 2012) carcinomas have 
been shown to increase prostate cancer risk by 69% and 15%, respectively. Also, it has 
been reported that previous lung cancer and melanoma increased the risk of prostate 
cancer by 56% and 50%, respectively (Bradford et al. 2010; Hayat et al. 2007).     
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1.3 The pathology of prostate cancer 
1.3.1 Prostate anatomy 
Prostate gland is a part of male’s reproductive and urinary system. Prostate is an oval 
shaped gland located at the base (or neck) of the bladder, surrounding the urethra as 
shown in Figure 1.4. It is surrounded by a capsule of connective tissue called prostatic 
capsule. The prostate gland can be divided either by lobe or by zone.  What is important 
clinically is the division of the prostate into 3 zones: the central zone surrounds the 
ejaculatory ducts and makes up to 25% of the total gland volume; the transitional zone 
surrounds the urethra accounting for 5% of the total prostate mass and is the primary site 
of benign prostatic hyperplasia (BPH), the peripheral zone is the body of the gland 
makes up 70% of prostate volume and is the most common location for 
adenocarcinomas (Figure 1.5) (Ashley Evan Ross 2016).    
 
Figure 1.4: Anatomy of the male reproductive and urinary system (Bethesda 2016).  
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Figure 1. 5: Illustration of Prostate gland zones; PZ = peripheral zone, TZ = transition 
zone, CZ = central zone. (Curran et al. 2007)  
 
1.3.2 Normal function of the prostate 
Sex accessory tissues including prostate, seminal vesicles, bulbourethral glands and 
ampulla glands are believed to play a major role in reproductive processes. The main 
important function of prostate gland is the production of a fluid that, together with sperm 
cells testicles, fluid from the seminal vesicle and fluids from other glands such as 
bulbourethral gland makes up the semen. Then, prostate muscles press the semen into 
the urethra for ejaculation (Plan & Michael 2015). One third of the total volume of 
semen contains several enzymes (such as PSA), citric acid and zinc. The fluid produced 
by prostate gland is acidic; but another component of semen from seminal vesicles 
makes semen alkaline to protect sperms and prolong their life time. Prostatic secretion is 
also important for proper functioning of fertility in men (Alan et al. 2015; Sadava & 
Freeman 2008).   
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1.3.3 Normal prostatic cells  
There are three main prostatic epithelium cell types: luminal cell, basal cell and 
neuroendocrine cells. Basal cell population acts as a stem cell reservoir to generate these 
three types of other cells (Figure 1.6) (Humphrey 2012).  
Laminal cells are the most predominant cells and constitute the exocrine compartment of 
prostate, secreting prostatic proteins such as PSA and prostatic acid phosphatase (PAP). 
These cells are androgen dependent cells and require androgen for their survival and 
viability, expressing high levels of androgen receptor (AR) (Foster et al. 2000). They 
also express cytokeratin (CK) 8 and CK18. As 95% of prostate adenocarcinomas were 
luminal phenotype, the increase expression of specific markers including PSA, PAP, 
CK8 and CK18 is expected in the majority of cancer cells (Denmeade, Lin & Isaacs 
1996).  
Basal cells are the second large population epithelial cell type in prostate located 
between basement membrane and luminal cells. Unlike luminal cells, these cells lack 
secretory activity and are unable to express AR and do not undergo apoptosis in 
response to androgen ablation (Bonkhoff & Remberger 1993; Okada et al. 1992). 
However, basal cells are able to either express high molecular weight protein markers 
such as CK14, CK5 and CD44 or factors that can protect against DNA damage such as 
free-radical scavenger GST-π (Harper et al. 1998).   
Neuroendocrine cells are the third cell type in prostate and located in all the epithelium 
of acini and ducts of prostate gland. These cells are androgen independent and can be 
distinguished by producing thyroid stimulating hormone, serotonin and chromogranin A 
(Abate-Shen & Shen 2000). Also, neuroendocrine cells express neuroendocrine factors 
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and neuropeptides that support proliferation of luminal cells (Harper et al. 1998). 
Several studies have suggested a positive correlation between the increase level of 
neuroendocrine factors and the advanced stage of prostate adenocarcinomas (Ruscica et 
al. 2007; Sagnak et al. 2011).  
 
 
 
 
 
 
Figure 1. 6: Three different cell types can be detected in prostate epithelium: Luminal 
cells, basal cells and neuroendocrine (NE) cells (Bok & Small 2002).  
Luminal cells 
Basal cells 
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1.3.4 Prostate cancer initiation 
1.3.4.1 Benign prostatic hyperplasia (BPH) 
Benign prostatic hyperplasia (BPH) is also known as benign prostate enlargement which 
is a non-malignant overgrowth of prostate cells and histologically diagnosed by 
proliferation of the cellular elements of the prostate (Figure 1.7). BPH is not a precursor 
for prostate cancer and is not caused by cancer (Bok & Small 2002). However, both 
BPH and prostate cancer have some similarities such as both require androgen 
stimulation for their growth and both are age related diseases (Sausville & Naslund 
2010).  BPH occurs in transition zone, a ring of tissue around the urethra and its growth 
is inward toward the prostate's core, constantly tightening around the urethra and 
associated with lower urinary tract symptoms (LUTS). BPH is hormonally dependent on 
dihydrotestosterone (DHT) and testosterone production occurring in aged men (Wise & 
Md 2001) (50% of men diagnosed with BPH are by age 60 years and it increases to 90% 
by age 85 years (Deters 2016). 
 
Figure 1. 7: Benign prostatic hyperplasia (BPH) (Bethesda 2016). 
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1.3.4.2 Prostatic Intraepithelial Neoplasia (PIN) 
Prostatic Intraepithelial Neoplasia (PIN) is a precancerous condition and sub stage of 
cellular transformation from a normal condition to malignant prostatic epithelium. PIN 
is identified by abnormal proliferation of cancer cells without invasion to surrounding 
stroma resulting in minimal changes that makes a variety of architectural and cytological 
aspect undistinguishable from carcinoma (School 2011). 
According to their cellular features and nuclear enlargement, PIN can be divided into 
two grades: low grade PIN and high grade PIN. Low grade PIN lesion is a well 
differentiated early invasive tumour with an intact or rare interrupted basal layer 
(Roehrborn 2008). High grade PIN lesion is poorly differentiated with secretory luminal 
cell population and frequent interruption of basal layer (Bostwick 1989). This lesion was 
divided into four different groups: Tufting which is the most common type, 
Micropapillary, Cribriform and flat (Foster & Ke 1997). Several studies have shown 
correlation between PIN and prostate cancer and suggested that high grade PIN is an 
important marker for detection of prostate cancer (Ayala & Ro 2007).  
1.3.4.3 Gleason grading system of prostate cancer 
Gleason score (GS) is a histological grading system used to describe the morphological 
changes in prostate cancer. GS proposed by Dr. David Gleason in 1960s and become the 
most common grading system to evaluate the prognosis of prostate cancer (Gleason & 
Mellinger 1974). 
In the Gleason grading, prostate cancer was classified according to their morphological 
appearance ranging from least aggressive (grade1) to the most aggressive cancer (grade 
5), representing the degree of loss of normal glandular tissue as shown in Figure 1.8. 
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Combined Gleason scores are a sum of primary score that represents the majority of 
tumour (>50%) and secondary score which represents the minority of tumour (<50%). 
Thus, the combined GS is a number ranging from 2-10, the highest GS is 10 and the 
lowest is 2. According to the differentiation, Gleason grading system has classified the 
scores into three groups: well differentiated (Gleason scores <6), moderately 
differentiated (Gleason scores 6-7) and poorly differentiated (Gleason scores 8-10). 
Combined GS appears to be the most commonly prognostic indicator in prostate 
carcinomas (Roehrborn 2008). 
 
Figure 1. 8: Gleason score grading system. Microscopic determination of the loss of 
normal prostate glandular, ranging from least aggressive (grade1) to the most aggressive 
cancer (grade 5), representing the degree of loss of normal glandular tissue (Gleason & 
Mellinger 1974). 
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1.3.5 Prostate cancer cell lines 
There are six different prostate cell lines widely used in laboratory studies including the 
work described in this study. These cell lines, which represent different spectrums of 
prostatic conditions, varied from benign PNT2, through low malignant LNCaP, 
moderately malignant 22RV1, to highly malignant cell lines Du145, PC-3 and PC3-M.  
1.3.5.1 PNT-2 
PNT-2 cell line is a normal human prostate cell line derived from prostate epithelial cells 
of a 33-year-old man and established by immortalization through transfection with 
plasmid containing simian virus 40 genome (SV40) (Cussenot et al. 1991; Sobel & 
Sadar 2005). Successful immortalisation was achieved only with SV40 expressing both 
large T and small t oncogenes, while attempts to immortalise with a vector expressing 
SV40 large T alone have given a few strains showing no extended lifespan and no cells 
which overcame the crisis (Cussenot et al. 1991). This cell line has a well differentiated 
morphology, expressing PSA, PAP, CK8, 18 and 19.  PNT-2 has no tumorigenic effect 
when inoculated in nude mice (Berthon et al. 1995).  
1.3.5.2   LNCaP 
LNCaP cell line is derived from a lymph node metastasis of prostate cancer from a 50-
year-old man in 1977 (Sobel & Sadar 2005). This cell line is androgen sensitive 
expressing high level of AR (in order increase growth rate), PSA and PAP. Previous 
studies in mice showed that LNCaP did form tumours and no metastatic spread was 
observed in any of the mice given injections (Tuxhorn et al. 2002; Zheng et al. 2010).  
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1.3.5.3 22RV-1  
22RV-1 is a moderately malignant, androgen responsive prostate epithelial cell line 
derived from a human prostatic carcinoma xenograft. These cells are being proliferated 
in mice after castration-induced regression and relapse of the parental, androgen-
dependent CWR22 xenograft. This cell line express high level of PSA. The cell 
population doubling time is approximately 49-56 hours (Sramkoski et al. 1999). 
1.3.5.4 Du145  
Du145 is derived from moderately-differentiated prostate cancer that metastasized to 
central nervous system of a 69-year-old man (Sobel & Sadar 2005).  This cell line 
express filament protein, PAP, CK5, 8 and 18; however, PSA, AR and glandular 
kallikrein are not present (Carpten et al. 2002; Nabha et al. 2005).  Several animal 
studies have shown that tumours were formed when Du145 cells were injected 
subcutaneously in nude mice. The cell population doubling time is approximately 33 
hours (Van Bokhoven et al. 2003).  
1.3.5.5 PC-3 and PC3-M 
PC-3 cells are poorly-differentiated bone marrow metastasis of prostate cancer (Kaighn 
et al. 1979; Sobel & Sadar 2005). PC3-M cell line was isolated from the most aggressive 
featured sub-population from liver metastasis produced in nude mice when injected with 
parental cell line PC-3 (Shevrin, Gorny & Kukreja 1989). Therefore, there are some 
similarities between PC-3 and PC3-M, but PC3-M is more aggressive than other prostate 
malignant cell lines.  Animal studies show that tumour growth in female nude mice due 
to the possibility that PC-3 and PC3-M are androgen-independent. Evidence showed that 
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these cell lines can exhibit high rate of tumorigenicity and metastasis in nude mice 
(Kozlowski et al. 1984).  
1.4 Androgens and androgen receptors in prostate cancer  
1.4.1 Androgens and androgen receptor in normal prostate 
Androgen receptor (AR) is a 110 kDa ligand-activated nuclear transcription factor that 
belongs to a large family of so-called nuclear receptor proteins and structurally similar to 
the estrogen receptor (Shah et al. 2004; Stanbrough et al. 2001).The current model of 
action of the androgens and the AR is demonstrated in Figure 1.9 (Tan et al. 2015).  AR 
is expressed by secretory cells in prostate and its function relies on the action of 
androgens. The hypothalamus releases gonadotropin releasing hormone (GnRH) leading 
to secretion of luteinizing hormone (LH) from pituitary gland. After that, LH stimulates 
Leydig cells in testes to secret testosterone which is the main androgen. Also, the release 
of corticotrophin releasing hormone (CRH) from the hypothalamus stimulates the 
pituitary gland to produce adrenocorticotropic hormone (ACTH) which can secrete and 
stimulate the production of other androgens. Dihydrotestosterone (DHT) is a mediator of 
prostate growth. DHT is synthesized by the enzyme 5α-reductase from testosterone in 
the prostate, testes, adrenal gland and hair follicles. DHT has a stronger binding affinity 
for the AR than testosterone. Then, the complex translocate to the nucleus and regulate 
the expression of target genes through binding to androgen response elements (AREs) 
(Heinlein & Chang 2002, 2004; Roy et al. 1999).  
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Figure 1. 9: Ligand-dependent activation of the androgen receptor. Testosterone is 
transported to target tissues such as the prostate and becomes converted to 
dihydrotestosterone (DHT) by 5-α-reductase. DHT binds to the ligand-binding pocket 
and promotes the dissociation of heat-shock proteins (HSPs) from the AR. The AR then 
translocates into the nucleus, dimerizes and binds to the androgen response element 
(ARE) in the promoter region of target genes such as prostate-specific antigen (PSA) 
and TMPRSS2. At the promoter, the AR is able to recruit members of the basal 
transcription machinery [such as TATA-box-binding protein (TBP) and transcription 
factor IIF (TFIIF)] in addition to other coregulators such as members of the p160 family 
of coactivators and cAMP-response element-binding protein (CREB)-binding protein 
(CBP). SHBG: serum sex hormonebinding globulin (Tan et al. 2015). 
Introduction 
42 | P a g e  
 
1.4.2 AR and prostate carcinogenesis 
Growth of prostate cancer cells requires androgen, similar to normal prostate cells. 
Androgens and AR are main mediators for the ratio of cell proliferation to cell death 
(Denmeade, Lin & Isaacs 1996; Feldman & Feldman 2001). It has been shown that 
androgen depletion had led to regression of prostate cancer (Feldman & Feldman 2001). 
The increased expression of AR is associated with diagnosed, but untreated prostate 
cancer. Similarly, reduced patient survival has been found to correlate with 
overexpression of AR (Ruizeveld de Winter et al. 1994; Schatzl et al. 2002). However, 
Lee and Chang reported that higher AR was correlated with low GS. The expression of 
ARs throughout the progression of prostate cancer remain controversial which might be 
because of variable responses to endocrine therapy (Karantanos, Corn & Thompson 
2013; Lee & Chang 2003; Marques et al. 2010). Generally, AR expression may not 
correlate with prostate cancer development.  
Nearly 50 years ago, Charles Huggins found that castration induced the regression of 
prostate cancer (Huggins 1967). Until now androgen depletion has been used as 
therapeutic intervention to treat prostate cancer either by surgical removal of the testes 
or by interfering with the release of the pituitary LH that stimulate the secretion of 
androgens in Leydig cells. This therapy is very effective in androgen-dependent cancer, 
but some cells proliferate and grow relatively or completely independent of androgens 
and go on to metastasize and eventually become androgen-independent cancer (Debes & 
Tindall 2004). This might be because of incomplete blockage of AR, AR mutations, AR 
amplifications or AR splice variant expression (Scher & Sawyers 2005).  AR deprivation 
might be useful for some patients, but has not been yet shown to prolong survival (Fang, 
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Merrick & Wallner 2010; Mayor 2015).  Recently, a study showed the association 
between androgen ablation in the treatment of prostate cancer and the increased risk of 
Alzheimer’s disease in a general population cohort (Nead et al. 2016).        
1.5  Potential prognostic and diagnostic markers for prostate cancer 
Most prostate cancer diagnosis and treatment decisions are first based on screening with 
serum PSA level or digital rectal examination (DRE) and subsequent biopsies for 
histopathological grading (Bretton 1994; NHS 2015b). However, each procedure has its 
limitations leading to an over-biopsy for diagnosis, an over-treatment of low-risk 
patients and non-essential surgery such as radical prostatectomies (Caram, Skolarus & 
Cooney 2016; Moyer 2012; Schroder 2011; Schroder et al. 2009). Available biomarkers 
can be used for making speedy and correct treatment strategy for individual patients to 
detect advance disease at an earlier stage and to predict the outcomes of patients. Blood, 
urine, semen and tissues can be used to detect biomarkers for prostate cancer. Therefore, 
identification of novel biomarkers should be used to predict the severity of malignancy 
and its progression, to distinguish between the benign and the malignant nature of each 
case, to monitor response to treatment and to predict the probability of recurrence. It 
should be non-invasive, consistent, economical and easily accessible (Velonas et al. 
2013). 
1.5.1 Over-diagnosis and over-treatment of prostate cancer 
Although the widespread screening and diagnostic practices did lead to a degree of 
decline in mortality rates in some countries, many prostate cancer cases were not picked 
up in other countries and it has now become the most common male cancer in the 
developed world (Carter et al. 2013). In oncology, over-diagnosis is a widespread 
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problem in prostate (Klotz 2013), lung (Esserman et al. 2014) and breast cancer (Welch 
& Black 2010). Over-diagnosis can lead to over-treatment and cause significant anxiety 
and unnecessary decrements in patient quality of life, particular with regarding to sexual 
dysfunction and urinary incontinence (Capitanio et al. 2008; Draisma et al. 2009). In the 
European Randomized study of Screening for Prostate Cancer (ERSPC), it was revealed 
that 20% mortality was reduced among the 240,000 men in the European screening 
program. However, for one life saved, 48 men were over treated (Schröder et al. 2009). 
To address this problem, there are 4 strategies to support decision-making about 
screening and treatment; to identify the highest risk patient, to minimize treatment for 
minimal-risk patients, to targeting preventive interventions and development and to 
validate new biomarkers that can help to identify progression of cancer and distinguish 
between benign and malignant lesion to minimal-risk cancers (Klotz 2013). Also, patient 
education is considered as one of the main critical solutions for this problem.  
 Recently, active surveillance has been used which is to manage patients with ≤ GS6 or 
≤GS7, serial PSA (<10 ng/ml) and periodic biopsy (Soloway et al. 2010). Although 
active surveillance become widely used (Bethesda 2011), this approach still depends on 
PSA assessment and re-biopsies. This strategy may lead to unnecessary biopsies (a very 
invasive procedure) that carry other side risks such as decrement in quality of life and 
subsequent infection (Nam et al. ; Nam et al. 2010). Therefore, the ideal biomarkers hold 
the promise to provide a new way of disease stratification for prostate cancer and hence 
the biopsy procedure and nonessential treatments can be avoided. 
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1.5.2 Biomarkers in prostate cancer  
1.5.2.1 Prostatic acid phosphatase (PAP) 
Prostatic acid phosphatase (PAP) is a 100 kDa glycoprotein found in large amount in 
seminal fluid. It had been suggested that PAP was significantly higher in adult prostate 
cancer patients. In 1941, the correlation between prostate cancer and increased level of 
PAP was documented (Huggins & Hodges 1941; Huggins & Hodges 2002). Prior to the 
introduction of PSA, PAP was used as a biomarker to diagnose prostate cancer patients 
in the 1940s and 1950s (Heller 1987). Since PAP levels elevated in non-prostatic disease 
or benign conditions of prostate, PAP as prognostic marker was overlooked (Taira et al. 
2007).Therefore, PAP was replaced by PSA due to its poor sensitivity for screening and 
diagnosing prostate cancer (Kontturi 1991).  
1.5.2.2 Prostatic specific antigen (PSA)  
PSA or human kallikrein 3 (hK3) is a 33 kDa serine protease of the tissue kallikrein 
family produced by the epithelial cells of prostate gland into the secretory duct to 
contribute to liquefy seminal fluid and increase the sperm mobility. In prostate cancer, 
the basal cell layer disrupted allowing PSA to leak into blood leading to elevated levels 
of PSA. The incidence and mortality rate of prostate cancer increased in the USA 
throughout the entire 1980s and peaked in 1991 (Brawley 2012). In 1980s, Roswell Park 
Memorial Institute showed that elevated levels of PSA were correlated with BPH and 
prostate cancer (Papsidero et al. 1980). After that, PAP was dropped as a screening tool. 
Since 1992, the serum PSA screen was used on a wide population. This marker helped in 
early diagnosis of prostate cancer and thus contributed to improvements in subsequent 5-
year survival rates (Adamson et al. 2003; Barry 2001; Moore et al. 2009). Currently PSA 
Introduction 
46 | P a g e  
 
is the most common marker used for both diagnosis and treatment management (Sharifi, 
Gulley & Dahut 2005). Although the widespread screening for PSA did lead to a degree 
of decline in mortality rates in some countries by at least 21% (Schröder et al. 2014), 
many prostate cancer cases were not picked up by PSA screening (Ilic et al. 2013; PHE 
2016a). Using a PSA cutoff level of 4 ng/ml as an indicator for prostate biopsy, the 
specificity and sensitivity of PSA were estimated about 60-70% and 40-50%, 
respectively. However, several separate studies even suggested that PSA screening had 
only very limited or even no survival benefits, when a PSA cutoff level of 4 ng/ml was 
used to recommend a prostate biopsy (or not) (Andriole  et al. 2009; Kim & Andriole 
2015; Moore et al. 2009). Some other research studies show that using a cut-off point ≥ 
10ng/ml increases its specificity and sensitivity to 95% and 72%, respectively. The 
results highlight that there is no distinct PSA cut-off to distinguish between the presence 
and absence of prostate cancer, but the best results were obtained and used for PSA cut 
off of 10 ng/ml (Kim & Andriole 2015; Vukotic et al. 2005). PSA levels may also be 
increased in some benign prostatic diseases, such as prostatitis and BPH or some 
medications and environmental factors. Since PSA is produced and secreted by both 
benign and malignant prostate cells, the serum level of PSA can only reflect the size of 
the prostate gland, it cannot be used to distinguish the benign or malignant nature of the 
cells or to reflect different stage of prostate cancer. To increase the accuracy of using 
PSA as a screening tool, different molecular forms of PSA have been measured such as 
total PSA (tPSA) which is a sum of bound and unbound PSA. Unfortunately, it still 
produces false positives or negatives results and failed to meet the appropriate biomarker 
for prostate cancer.  Thus the real benefit of the widespread use of PSA screening is still 
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debatable and the reliability of PSA as a prostate cancer marker is in serious question to 
be used as foundation for making accurate diagnosis and therapeutic decisions. 
Therefore, a reliable and accurate diagnostic or prognostic marker (Adamson et al. 2003; 
Forootan et al. 2007; Jing et al. 2001) that can be used to distinguish between benign and 
malignant prostatic disease is urgently needed for making speedy and correct treatment 
decisions (Bhavsar, McCue & Birbe 2013; Moore et al. 2009; Sardana & Diamandis 
2012). Apart from PSA, there are many different biomarkers have been reported and 
their prognostic significance was studied such as human kallikrien 2 (hK2), transforming 
growth factor-β1 (TGF-β1), Interleukin-6 (IL-6), prostate cancer antigen 3 (PCA3), early 
prostate cancer antigen 2 (EPCA2), TMPRSS2-ERG fusion gene, S100 family protein, 
prostate stem cell antigen (PSCA) and fatty acid binding protein 5 (FABP5).  
1.5.2.3 Human Kallikrein 2 (hK2) 
hK2 is a serum protease with trypsin-like specificity that belongs to the same family as 
PSA. hK2 and PSA share approximately 80% amino acids in the sequence and both are 
regulated by a similar mechanism (Yousef & Diamandis 2001). hK2 is expressed in a 
high level and is restricted to prostate. hK2 was used as a biomarker for prostate cancer 
since the expression of hK2 is higher in malignant cases when compared with benign 
tissues, however it is not superior to PSA (Catalona et al. 1995).  Previous study has 
shown that hK2 mRNA was upregulated in highly malignant cells, while the PSA 
mRNA was down-regulated (Lintula et al. 2005). In 1999, Partin et al. examined the 
correlation between hK2 levels and prostate cancer using hK2/free PSA ratio and found 
that it could be detected in 40% of prostate cancer patients with PSA < 4 ng/ml. It has 
been suggested to be a promising biomarker for predicting the outcomes of prostate 
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cancer patients (Partin et al. 1999). However, several studies showed that hK2 cannot 
discriminate pathological stage or unable to prove additional value over existing 
variables (Stephan et al. 2006; Vaisanen et al. 2006). Therefore, further investigation is 
needed to confirm its ability to be used as prognostic marker (Hong 2014).  
1.5.2.4 Transforming growth factor-β1 (TGF-β1) 
TGF-β1 is involved in the regulation of immune response, cellular proliferation, 
chemotaxis and angiogenesis. Elevated levels of TGF-β1 have been found in various 
cancers and the cytokines in the TGF-β1 family implicated in progression of several 
cancer types (dos Reis et al. 2011; Zarzynska 2014). Increased expression of TGF-β1 in 
prostate cancer was associated with highly malignant cases, metastasis and invasion. No 
correlation was observed between plasma levels of TGF-β1 and stage of prostate cancer 
(Qin et al. 2013; Shariat et al. 2001). More investigations are needed on the potential 
value of TGF-β1 as a prognostic marker (Y 2010).  
1.5.2.5 Interleukin-6 (IL-6) 
IL-6 is involved in the regulation of immune defence mechanism and bone turnover 
(Paul 1991). Numerous studies showed that the increased expression of IL-6 is 
correlated with the progression of prostate cancer through inhibition of cancer cell 
apoptosis and drug resistance (Zhang & Adachi 1999). Elevated levels of IL-6 have been 
found in advanced prostate cancer as well as other different cancer types such as breast 
cancer (Zhang & Adachi 1999), colorectal cancer (Waldner, Foersch & Neurath 2012) 
and ovarian cancer (Isobe et al. 2015). Treatment response to chemotherapy was better 
in patients with low IL-6 than those with high levels of IL-6 (Giri, Ozen & Ittmann 
2001). Therefore, IL-6 can be used as a potential therapeutic target by blocking IL-6 
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signalling. Further studies are needed to assess the therapeutic efficacy of anti-IL-6 
therapy.  
1.5.2.6  Prostate cancer antigen 3 (PCA3) 
PCA3 has been proven to be a useful biomarker that can be used alongside with PSA for 
more accurate diagnosis  (Van Gils et al. 2007). This non-coding RNA is restricted to 
the prostate and can be detected in prostatic fluids. Some studies showed that increased 
expression of PCA3 in 90% of biopsies from prostate cancer patients compared to those 
in benign cases (Salagierski & Schalken 2012). Furthermore, using PCA3 urine tests 
increased specificity and sensitivity for the diagnosis of prostate cancer (Day et al. 2011; 
Luo et al. 2014). However, since the effectiveness of this test depends on a full massage 
of prostate gland before the urine sample is taken, its test results may be varied amongst 
different examiners (CRUK 2016a). Although, PCA3 is commercially available as a 
diagnostic marker, it does not appear to have any prognostic value.     
1.5.2.7 Early prostate cancer antigen (EPCA) 
EPCA is a nuclear structural protein expressed in prostate adenocarcinomas. Elevated 
levels of EPCA in blood has been correlated with tumour progression of prostate cancer 
(Zhao, Zeng & Zhong 2010). Immunohistochemistry study suggested that EPCA has the 
potential to predict prostate cancer 5 years earlier than current protocols. However, some 
other studies showed that tissue EPCA2 staining was not correlated with tumour stage 
and Gleason scores in cases with prostate cancer (Dhir et al. 2004; Zhao et al. 2012).   
1.5.2.8 TMPRSS2-ERG gene fusion  
TMPRSS2-ERG is a transmembrane serine protease which is the first prostate gene 
fusion and the most frequent gene fusion in prostate cancer (Hessels et al. 2007). 
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biostatistical method called cancer outlier profile analysis (COPA) showed a strong 
outlier profiles for v-ets erythroblastosis virus E26 oncogene (ERG) in 57% of prostate 
cancer cases. This was in concordance with the results of a study where prostate cancer–
associated ERG overexpression was found in 72% of prostate cancer cases. In >90% of 
the cases that overexpression of ERG, a fusion of the 5′-untranslated region of the 
prostate-specific and androgen-regulated transmembrane-serine protease gene 
(TMPRSS2) with this fusion was found (Petrovics et al. 2005).  One study found that a 
strong correlation between TMPRSS2-ERG gene fusion and high Gleason scores 
(Rajput et al. 2007). However, another study showed that no association with Gleason 
score (Mosquera et al. 2007). Controversial results have been reported in many research 
studies for correlations between TMPRSS2-ERG and prognosis (De Muga et al. 2012). 
Therefore, this test is not available for clinical diagnosis and some other evidences did 
not support the prognostic significance of TMPRSS2-ERG.  
1.5.2.9 S100 protein family  
S100 protein family is also known as calcium binding protein family which is 10,000 
kDa protein in 100% saturated ammonium sulphate. They involve in many biological 
activities such as inflammation, differentiation, invasion or migration (Donato 2003). 
Dysregulation of several S100 family members has been recognized in most of cancer 
such as S100P (Mousses et al. 2002). In prostate cancer, multiple S100 family member’s 
overexpression was detected including S100A2, S100A4, S100A8, S100A9 and 
S100A11 (Ke et al. 1997; Rehman et al. 2005). Although increased expression of these 
S100 family members was detected in prostate cancer, no significant association with 
poor patient survival was observed.  
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1.5.2.10 Prostate stem cell antigen (PSCA) 
PSCA is a member of a family so-called Thy-lyLy-6 of glycosyl-phosphatidyl-inositol. 
It has been shown that PSCA is predominantly prostate specific and its upregulation in 
prostate cancer xenografts (Ramirez, Nelson & Evans 2008; Reiter et al. 1998).  Another 
study shows that PSCA overexpression is associated with high Gleason scores and 
metastatic progression, but the cause for increased expression of PSCA is still unknown 
(Han et al. 2004). Since, PSCA is normally expressed in the basal cells of normal 
prostate, the expression of PSCA in prostate cancer can be an indication that cancer arise 
from transformation of basal cells (Bonkhoff & Remberger 1996).     
1.5.2.11 Fatty acid binding protein 5 (FABP5) 
FABP5 is a 14 kDa cytosolic protein which is a member of fatty acid binding protein 
family with high affinity to bind long chain fatty acids and other lipids. Previous studies 
showed that some FABPs were implicated in progression of several cancer types and 
could be used as tumour biomarkers (Boiteux et al. 2009; Hammamieh et al. 2005; 
Ohmachi et al. 2006). FABP5 is expressed most abundantly in the skin. However, its 
expression has been identified in a wide range of tissues including brain, liver, kidney, 
adipocyte, lung, testis, spleen, skeletal muscle and prostate.  Our previous studies have 
showed that FABP5 is a cancer promoting gene (Bao et al. 2013; Kawaguchi et al. 
2016a).  Jing et.al found that FABP5 was overexpressed in malignant prostate epithelial 
cell lines and able to develop metastasis in vivo when transfected into non-metastatic rat 
cells. Furthermore, FABP5 played a crucial promoting role in tumorigenicity and 
metastasis of prostate cancer by facilitating angiogenesis through up-regulating VEGF 
gene (Jing et al. 2001; Jing et al. 2000). We also showed that the suppression of VEGF 
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expression has been detected in these transfected cell lines. Further investigation with 
staining of FABP5 showed a positive association between the increase expression of 
FABP5 and the increase degree of malignancies. FABP5 was also involved in malignant 
progression of pancreatic cancer (Sinha et al. 1999). 
 
1.6 Fatty acids, fatty acid binding protein family and prostate 
cancer 
1.6.1 Fatty acids 
Fatty acids play a key role in metabolic regulation and are essential components for all 
membranes (Berg, Tymoczko & Stryer 2002; Rustan & Drevon 2001).  In addition, fatty 
acids are important for mechanical protection, electrical and thermal insulation (Drevon 
2005). Fatty acids can act through enzymatic and transcriptional network to control gene 
expression (Jump 2004; Pegorier, Le May & Girard 2004). The most common major 
fatty acids in plant and animal are linoleic acids and arachidonic acids. Also, 
eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) are considered to be 
major fatty acids in fish oil (Berg, Tymoczko & Stryer 2002). Free fatty acids are 
released during digestion and absorbed in the small intestine then re-esterified to 
triacylglycerols (Rustan & Drevon 2001). Free fatty acids are taken up into cells by 
protein carrier and transported intracellularly via fatty acid binding proteins (Rustan & 
Drevon 2001).    
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1.6.2 Fatty acids and prostate cancer 
Prostate cancer has become the most common male cancer in Western developed 
nations. Fat consumption is highest in men in Europe and North America showing 
around 40% of total energy intake is obtained from their diet (Micha et al. 2014; NHS 
2015a). Several studies showed the correlation between dietary fat intake and prostate 
cancer (Crowe et al. 2008; Di Sebastiano & Mourtzakis 2014). The same was true when 
Western diet was introduced to Japanese diet, where their traditional diet is low in fat. 
The incidence of prostate cancer was significantly increased and the high levels of fat 
were consumed the more likely to develop aggressive prostate cancer (Marks et al. 
2004).  Most recent survey of 1,854 results on patients diagnosed with prostate cancer 
between 2004 and 2009 in North Carolina showed that the increased saturated fat intake 
was associated with aggressive prostate cancer (UoNCHCS 19 April 2016). Conversely, 
a study found that there is no correlation between prostate cancer risk and dietary fat 
intake (Crowe et al. 2008).  
1.6.3 Fatty acid binding protein family (FABPs) 
FABPs are intracellular lipids chaperones that control lipid responses in cells and linked 
to metabolic and inflammatory pathways. FABPs belong to a large family so-called 
iLPB which is divided into 4 subfamilies according to the type of ligands to which they 
bind. Since the first discovery of FABPs in 1972 (Ockner et al. 1972), 12 members of 
the FABP family have been identified so far and 2 of them are restricted to fish 
(Smathers & Petersen 2011). The nomenclature of each member was after the tissue in 
which they were first isolated or prominently expressed. However, FABPs can express 
in different human organs either singly or co-expressed with 1 or more other family 
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members (Chmurzynska 2006; Furuhashi & Hotamisligil 2008; Smathers & Petersen 
2011). FABPs serve to bind a variety of ligands such as saturated, unsaturated long 
chain fatty acids, retinoid and other lipids with high affinity.  FABPs are abundantly 
expressed 14-15 kDa proteins in tissue that is highly active in fatty acid uptake. But for 
other tissues that are less active in fatty acid metabolism, FABPs are not highly 
expressed. FABPs expression is usually regulated at transcriptional level in a given cell 
type reflecting the capacity of their lipid-metabolising in adipocytes, hepatocytes and 
cardiomyocytes. It has been suggested that FABPs make up between 1% and 5% of all 
soluble cytosolic proteins (Chmurzynska 2006; Furuhashi & Hotamisligil 2008; 
Smathers & Petersen 2011).  
1.6.4 General functions of FABPs 
Several studies suggested that the presence of FABPs inside the cell is essential for fatty 
acids storage and import; making the fatty acids more soluble and preventing the 
detergent-like properties of high concentrations of fatty acid. Recently, numerous studies 
showed that FABPs are central regulators of lipid metabolism, immune response and 
inflammation. FABPs have been suggested to be involved in secretion, uptake and 
intracellular transport of lipids to subcellular-organelles, for example to the endoplasmic 
reticulum for signalling, to lipid droplet for storage or to the mitochondria for oxidation 
(Figure 1.10) (Furuhashi & Hotamisligil 2008; Smathers & Petersen 2011). In addition, 
they are involved in conversion of fatty acids to eicosanoid intermediates (Zimmer et al. 
2004). FABPs have the ability to access to the nucleus targeting fatty acids for 
transcriptional regulation such as the peroxisome proliferator-activated receptor (PPAR) 
family PPAR-α, PPAR-δ and PPAR-γ in the nuclear lumen (Forootan et al. 2016; 
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Hughes et al. 2015; Tan et al. 2002). Some FABP family members themselves are 
controlled by PPAR family which is liganded by fatty acids.  FABPs also have been 
involved in a wide range of associated diseases such as atherosclerosis, obesity, diabetes 
and cancer (Thumser, Moore & Plant 2014). FABPs have also been suggested to control 
cancer growth through co-ordination with other fatty acid transporters and carcinogens 
(Schachtrup et al. 2004), steroids (Gao et al. 2010),  hormones (Pinthus et al. 2007) and 
their derivatives (Chmurzynska 2006).    
 
Figure 1. 10: Putative functions of FABPs in the cell. FABPs have been proposed to 
play a role in the transport of lipids tospecific compartments in the cell: to lipid droplets 
for storage; to the endoplasmicreticulum for signalling, trafficking and membrane 
synthesis; to the mitochondria orperoxisome for oxidation; to cytosolic or other enzymes 
to regulate their activity;to the nucleus for the control of lipid-mediated transcriptional 
programs via nuclear hormone receptors (NHRs) (Furuhashi & Hotamisligil 2008). 
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1.6.5 Fatty acid binding proteins (FABPs) affinity and structure 
The structure of several FABPs was revealed based on X‑ray crystallography, nuclear 
magnetic resonance (NMR) and other biochemical techniques. FABP family has 15% to 
70% sequences identity between different members. Despite the differences in their 
protein sequences, all FABPs share identical three dimensional structures. Common to 
all FABPs is a 10-stranded antiparallel β‑barrel structure, organized into two orthogonal 
five-stranded β‑sheets. The binding pocket is located inside the β-barrel, the opening of 
which is capped on one side by the N‑terminal helix loop helix motif, and fatty acids are 
bound to the interior cavity as shown in Figure 1.11 (Chmurzynska 2006). The overall 
structure of FABP gene is highly conserved, consisting of 4 exons separated by 3 
introns. For all FABPs, the position of exons and introns are the same. All FABPs share 
a conserved three‑element fingerprint (Figure 1.12) (Smathers & Petersen 2011).    
All FABPs bind a variety of ligands such as saturated, unsaturated long chain fatty acids, 
retinoid and other lipids with high affinity (Storch & Thumser 2010).  Binding 
mechanism and binding affinity are based on the small structural differences between 
isoforms. Generally, the binding affinity increased with more hydrophobic ligands. 
Additionally, FABPs bind only one ligand per molecule of protein except FABP1 which 
can bind two ligands simultaneously.  FABP7 is highly selective for long chain fatty 
acids, whereas FABP1 has a binding capacity for different ligands from 
lysophospholipids to haem (Smathers & Petersen 2011). Chromosomal mapping of all 
FABPs show that FABP1, FABP2, FABP3, FABP6 and FABP7 exist on separate 
chromosome in the human, whereas FABP4, FABP5, FABP8, FABP9 and FABP12 are 
localized at chromosome (Chr) 8q21 as shown in Table 1.3 (Chmurzynska 2006).      
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Figure 1. 11: Crystal structure of ligand-bound FABPs. Ligand-binding FABPs are 
shown above (The figures were created using PyMOL). (a) FABP1; (b) FABP2; (c) 
FABP3; (d) FABP4; (e) FABP5; (f) FABP8; (g) FABP6; (h& i) FABP7 (Furuhashi & 
Hotamisligil 2008). 
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Figure 1. 12: Fingerprint for fatty acid binding proteins. potential functional domains 
include a nuclear localization signal (NLS) and its regulation site, nuclear export signal 
(NES) and a hormone-sensitive lipase (HSL) binding site17,26,100. The primary 
sequence of A‑FABP does not show a readily identifiable NLS. However, the signal 
could be found in the 3D structure of the protein and was mapped to three basic residues 
(K21, R30 and K31) located in the helix–loop–helix region, whose side chains shift their 
orientation upon ligand binding to form a functional NLS17. The NES is also not 
apparent in the primary sequence, but assembles in the tertiary structure from three 
nonadjacent leucine residues (L66, L86 and L91) to form a motif reminiscent to that of 
established NES (Furuhashi & Hotamisligil 2008). 
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Table 1.3: chromosomal localization of all human FABP genes and their distribution. 
 
 
 
Gene Chromosomal 
location 
No. of 
amino acids 
Protein localization 
FABP1 2p11 127 Liver, intestine, pancreas, 
kidney, lung and stomach. 
FABP2 4q28–q31 132 Intestine and liver. 
FABP3 1p33–p31 133 Cardiac and skeletal muscle, 
brain, kidney, lung, stomach, 
testis, adrenal gland, mammary 
gland, placenta, ovary, brown 
adipose tissue. 
FABP4 8q21 132 Adipocytes, macrophages, 
dendritic cells, skeletal muscle 
fibres and prostate. 
 
FABP5         8q21.13 135 Skin, tongue, adipocyte, 
dendritic cells, mammary 
gland, stomach, intestine, 
kidney, lung, heart, skeletal 
muscle, testis, retina, lens, 
spleen, placenta and prostate. 
FABP6 5q23–q35 128 Ileum, ovary, adrenal gland, 
stomach 
FABP7 6q22–q23         132 Brain, central nervous 
system (CNS), glial cell, 
retina, mammary gland 
         FABP8 8q21.3–q22.1         132 Peripheral nervous system, 
Schwann cells 
FABP9 8q21.13 132 Testis, salivary gland, 
mammary gland. 
FABP12 8q21.13 140 Retinoblastoma cell, a retina 
(ganglion and inner nuclear 
layer cells), testicular germ 
cells cerebral cortex. 
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1.6.6 Human fatty acid binding proteins in health and disease 
 
1.6.6.1 FABP1  
FABP1 is abundantly expressed in liver tissue representing 5% of all cytosolic protein in 
hepatocytes, but is also expressed in different tissues including those of intestine, 
kidney, pancreas and lung organs (Chmurzynska 2006). FABP1 plays a key role in the 
hepatic β-oxidation of unesterified fatty acids via the regulation of expression or fatty 
acid trafficking (Atshaves et al. 2010). It has been shown that FABP1 is required to 
maintain lipid droplet in hepatic stellate cells (HSCs). FABP1 downregulation results in 
HSC secretion of collagen and proliferation, activation and loss of lipid droplets leading 
to hepatic fibrogenesis (Chen et al. 2013). Unlike the other members, FABP1 has a 
binding capacity for a wide range of ligands, uniquely binds to two ligands or various 
hydrophobic molecules such bile acids and cholesterol (Storch 1993).  
A study addressed the positive correlation between serum FABP1 levels and obesity and 
insulin resistance in Chinese young adults (Shi et al. 2012).  Increased expression of 
FABP1 has been recognised in several cancer types, including liver, colorectal, lung and 
gastric cancers (Ku et al. 2016; Lawrie et al. 2004; Wang et al. 2015). Furthermore, 
FABP1 play a key role in metastasis and invasiveness of breast cancer and serves as 
diagnostic biomarker for breast cancer. Recent study has shown a positive correlation 
between the expression of FABP1 and VEGF expression in hepatocellular carcinoma 
(HCC), suggesting that FABP1 could serve as a potential therapeutic target for HCC 
therapy (Dong et al. 2007; Ku et al. 2016).     
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1.6.6.2    FABP2 
In addition to FABP1, FABP2 is also mostly expressed in intestinal enterocytes, 
representing 1-2% of all cytosolic proteins. FABP2 is highly expressed in jejunum 
which play a key role in lipid adsorption (Agellon, Toth & Thomson 2002). Generally, 
FABP2 is involved in the binding and transport of hydrophobic fatty acids from cell 
membrane to endoplasmic reticulum. Also, FABP2 is guiding fatty acids to the 
mitochondria for energy sources in the enterocytes.  However, some other reports 
recognised a lower fatty acids uptake by enterocytes characterized by a high level of 
FABP2 (Gajda & Storch 2015). Increased levels of FABP2 has been linked to increasing 
degrees of villous atrophy in coeliac disease (Adriaanse et al. 2013; Uhde et al. 2016). 
The overexpression of FABP2 affects the intracellular processes needed for adequate 
intestinal fat adsorption and transport. Most recent studies have linked FABP2 with 
atherosclerosis in type-2 diabetes mellitus patients and pneumatosis intestinalis disease 
(Khattab et al. 2016; Matsumoto et al. 2016).  
1.6.6.3 FABP3  
The main cells expressing FABP3 are myocytes, although it also expressed in a wide 
range of tissues including skeletal muscle, brain, testes and lung (Storch & Thumser 
2010). FABP3 plays several key roles in fatty acids transport, cell signalling, cell growth 
and gene expression (Besnard et al. 2002). It has been suggested that FABP3 is a 
myokine that can contribute to regulating energy supply to heart (Binas et al. 1999), 
endocrine paracrine signalling (Thumser, Moore & Plant 2014). The main function for 
FABP3 is to traffic fatty acids towards the mitochondria (Smathers & Petersen 2011).  
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FABP3 has been proven to be a reliable prognostic marker for the early diagnosis of 
myocardial infarction/acute coronary syndrome (McMahon et al. 2012). Recent studies 
have shown that FABP3 involve in progression of several cancer types. In embryonic 
cancer cells, the elevated expression of FABP3 inhibits cell growth leading to apoptosis 
(Song et al. 2012). FABP3 acts as a tumour suppressor for breast cancer, showing the 
complete absence of FABP3 in breast cancer samples (Dean & Rhodes 2014). In 
contrast, increased expression of FABP3 is correlated with the development and 
aggressiveness of gastric cancer. Most recent study showed that overexpression of 
FABP3 is associated with poor prognosis in non-small cell lung cancer (NSCLC) (Tang 
et al. 2016).  
1.6.6.4 FABP4  
FABP4, is highly expressed in adipocytes and macrophages, recognized as an adipokine 
in addition to its traditional role in guiding fatty acids within cells. A study supported the 
role FABP4 as an adipokine has shown that interaction between adipocytes and 
macrophages increases secretion of FABP4 into the culture medium (Falcao-Pires et al. 
2012; Kralisch & Fasshauer 2013). 
It has been suggested that there is a positive correlation between FABP4 and  lipid 
metabolism or inflammation impacting on various diseases such as atherosclerosis, Non-
alcoholic fatty liver disease (NAFLD) and metabolic syndrome (Furuhashi et al. 2014). 
Numerous recent studies suggested that FABP4 has the potential to serve as a biomarker 
for acute myocardial infarction, as the presence of FABP4 in blood indicate that it is 
released from myocardium after cells are damaged (Pyati et al. 2016). FABP4 has the 
potential to serve as a prognostic marker for invasive bladder cancer (Ohlsson et al. 
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2005), and as a therapeutic target for metastasis of prostate cancer (Uehara et al. 2014). 
Also, increased expression of FABP4 has been linked to the poor prognosis in non-small 
cell lung cancer (NSCLC) and it was also evidenced FABP4 as prognostic predictor for 
NSCLC (Tang et al. 2016).    
1.6.6.5 FABP5 
FABP5 was identified in endothelial cells of different tissues including skin, heart, liver, 
placenta, skeletal muscle and renal medulla (Makowski & Hotamisligil 2005; Masouye, 
Saurat & Siegenthaler 1996). The absence of FABP5 in the liver during perinatal 
development was compensated by increasing levels of FABP4 (Owada et al. 2002). 
FABP5 plays a crucial role in progression of breast cancer (Powell et al. 2015). 
Knockdown of FABP5 expression in highly malignant prostate cell line significantly 
inhibited tumorigenicity and; the details of the role of FABP5 in prostate cancer has 
been discussed in section 1.5.2.11 (Adamson et al. 2003; Forootan et al. 2010; Morgan 
et al. 2008). Increased expression of FABP5 was also recognized in other cancer types 
such as colorectal cancer, oral squamous carcinoma and pancreatic cancer (Fang et al. 
2010; Kawaguchi et al. 2016b; Sinha et al. 1999).    
1.6.6.6 FABP6  
FABP6 is abundantly expressed in the ileum, but it is also expressed in placenta, ovaries 
and adrenal gland.  FABP6 plays a central role in binding and trafficking bile acids in 
ileal epithelium cells to catalyse the cholesterol, but also can bind and transport fatty 
acids (Furuhashi & Hotamisligil 2008; Smathers & Petersen 2011). It has been 
suggested that when FABP6 exhibit high affinity for bile acids, it regulates bile acids 
homeostasis in the intestine (Chiang 2002; Grober et al. 1999).  
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As previously reported that bile acids have the ability to induce colon carcinogenesis, 
inflammation and apoptosis in colonic epithelial cells (Nagengast, Grubben & van 
Munster 1995; Zhu et al. 2016). Overexpression of FABP6 has been identified to be 
correlated with colorectal cancer and adenomas when compared to normal epithelium, 
suggesting that FABP6 may play a promoting role in early colorectal carcinogenesis 
(Ohmachi et al. 2006).  It has been shown a positive correlation between the expression 
of FABP6 and the renal cell carcinoma and bladder cancer (Aaboe et al. 2005; Schrödter 
et al. 2016). FABP6 has not been previously reported to be related to progression of 
prostate cancer. Therefore, any factors that may affect the expression of FABP6 may 
significantly contribute to the pathogenesis of different diseases.  
1.6.6.7 FABP7  
FABP7 is mainly expressed in radial glia cells in brain tissue, it is not known yet 
whether it can be expressed in tissues other than brain (Mita et al. 2007; Sharifi et al. 
2011). FABP7 can be distinguished from other FABP family members by its strong 
affinity with n-3 polyunsaturated fatty acids which is an essential nutrient for central 
nervous system (Balendiran et al. 2000). Additionally, FABP7 does not bind retinoic 
acid or palmitic acid, but affinities for arachidonic acid and oleic acid are almost 
0.25µM and 4µM, respectively (Smathers & Petersen 2011).  
Overexpression of FABP7 is associated with different pathological conditions such as 
Down’s syndrome, schizophrenia and cancer (Sánchez-Font et al. 2003; Shimamoto et 
al. 2014). Increased expression of FABP7 has been recognized in malignant glioma cells 
and associated with the development and invasion of brain tumour (De Rosa et al. 2012). 
In addition, expression of FABP7 has been linked to poor prognosis of breast cancer and 
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renal carcinoma (Alshareeda et al. 2012; Teratani et al. 2007).  A research study has 
revealed that MAPK/ERK and PKC pathways in melanoma regulate FABP7, suggesting 
that FABP7 is correlated with tumour progression of melanoma (Slipicevic et al. 2008).   
1.6.6.8 FABP8 
FABP8 is highly expressed in peripheral nervous system myelin, but also expressed in 
central nervous system myelin (Smathers & Petersen 2011; Storch & Thumser 2010). In 
addition to its traditional function of binding to long chain fatty acids, FABP8 stabilise 
myelin membrane and involves in membrane biogenesis. Apart from these, the function 
of FABP8 is largely unknown. An animal study has revealed that cholesterol is a likely 
ligand for FABP8 (Majava et al. 2010). FABP8 shares high sequence similarities of 
almost 67% to FABP4 (Furuhashi et al. 2014).  
1.6.6.9 FABP9  
FABP9 is highly expressed in the testis and has several important physiological roles in 
sperm development; including attachment of the acrosome to the sperm nucleus during 
fertilization and spermatogenesis in mammalian testis (Kido & Namiki 2000; Liu, Li & 
Godbout 2008; Oko & Morales 1994; Smathers & Petersen 2011). It has been suggested 
that FABP9 protect sperm fatty acids from oxidation to be able to fertilise oocytes. More 
studies are needed to investigate whether the level of immunoreactive FABP9 can be 
used as diagnostic or prognostic biomarker for any type of cancer or other diseases. 
FABP9 is a poorly understood protein and no previous study has addressed the role of 
FABP9 in human prostate cancer (Al Fayi et al. 2016).   
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1.6.6.10 FABP12 
FABP12 is highly expressed in ganglion cells in adult retina, suggesting that it may play 
a key role in the regulation of genes involved in adult retina (Liu, Li & Godbout 2008).  
It was believed that FABP9 is the only FABP family member expressed in testis; but 
several studies have shown the expression of FABP12 in testicular germ cells. FABP12 
is poorly understood because it has only been discovered recently, and no reports or 
articles on this protein function have been published.   
1.6.7 Therapeutic target of FABPs 
FABPs are promising targets for treatment of cancer, atherosclerosis, obesity, diabetes 
and metabolic syndrome (Furuhashi et al. 2007; Hoo et al. 2013; Miao et al. 2015; Rao 
et al. 2015). Several studies have been reported in developing novel specific and 
efficient FABPs inhibitors which can be potential drugs for different diseases including 
prostate cancer (Wang et al. 2014). For instance, FABP4 inhibitors were used to treat 
ovarian cancer or suppressing invasion and migration of this cancer (Nieman et al. 
2011).  Several studies created pharmacological agents to modify FABP4 function that 
may offer a new class of therapeutic agents for obesity, insulin resistance and 
atherosclerosis (Furuhashi et al. 2015; Furuhashi et al. 2014). Our group now is focusing 
on FABP5 to be used a novel target for therapy in castration-resistance prostate cancer. 
Novel FABP5 inhibitors have been used to establish an experimental treatment for 
castration resistant prostate cancer in nude mice by suppressing the biological activity of 
FABP5.    
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1.7 Hypothesis 
After FABP5 was proven to be a prognostic marker and potential treatment target (Bao 
et al. 2013; Forootan et al. 2016; Forootan et al. 2014; Morgan et al. 2008), a frequently 
asked question was whether any other FABP family proteins can also be used as 
diagnostic or prognostic markers for prostate cancer. 
In the first part of this study, investigations were performed to investigate this issue by 
addressing following questions: 
 Are any other FABPs overexpressed in a wide range of prostate cancer cells and 
tissues? 
 Are there any correlations between the increased levels of the possibly 
overexpressed FABPs and the combined GS of patients? 
 Are there any correlations between the increased levels of the overexpressed 
FABPs and AR index or PSA levels of prostate cancer patients? 
 Is there any correlation between the increased levels of the overexpressed FABPs 
and survival period of the patients after diagnosis? 
 What is the biological significance of the elevated expression of these FABPs in 
prostate cancer? 
1.8 Aim and scope 
 Assessment of potentially differential expression levels of all FABPs in six 
different benign and malignant cell lines by RT-quantitative PCR (qPCR) in 
mRNA level. 
 Comparison of differential expression levels of all FABP proteins in six different 
benign and malignant cell lines by Western blot in protein level. 
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 Detection of differential expression levels of candidate FABPs in benign and 
carcinoma prostate tissues using immunohistological staining. 
 Assessing the correlation of the increased expression levels of candidate FABPs 
in prostate carcinoma tissues with the degree of malignancy, as measured by 
Gleason score (degree of malignancy), PSA level, AR index and patient’s 
survival time using varies statistical analyses. 
 Assessing the correlation of survival time of the prostate cancer patients with the 
combined Gleason scores (degree of malignancy), PSA level, AR index using 
different statistical analyses. 
 Suppressing the highly expressed candidate FABPs in highly malignant prostate 
cancer cells, transiently and stably, using RNAi techniques. 
 Evaluation of the supressing effects of candidate FABPs on growth rate, 
invasiveness, migration and anchorage-independent growth of prostate cancer 
cell, in vitro, using proliferation assay, invasion assay, wound healing assay and 
soft agar assay, respectively.
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CHAPTER TWO: 
MATERIALS AND METHODS 
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2. Materials and Methods 
2.1 Cell culture 
 
2.1.1 Initiate cell culture from frozen stock 
For long term storage, seven different cell lines had been frozen down in liquid nitrogen. 
To start new cell culture, cryovials were collected from liquid nitrogen and placed on 
ice. Before seeding the cells to cell culture dishes, vials were carefully cleaned with 70% 
ethanol from outside. Because dimethyl sulphoxide (DMSO) in frozen cryopreserved 
cells was used to induce differentiation, we removed the DMSO by diluting thawed cells 
in 20ml of fresh medium and centrifuged at 91 ×g for 3 minutes, the supernatant was 
decanted gently, and the cell pellet was re-suspended in 10 ml fresh medium in a 25 cm2 
flask and maintained in humidified incubator with 5% CO2 at 37
ºC.  
 
2.1.2 Cell lines and culture condition  
 
The following seven cell lines were used in this study: MCF7 breast cancer cell lines 
(the positive control for FABP6), benign prostate epithelial cell line PNT-2, weakly 
malignant cell line LNCaP, moderately malignant cell line 22RV-1 and highly malignant 
cell lines Du145, PC-3 and PC3-M. Rat testis extract (Santa Cruz Biotechnology, 
Germany) was used as a positive control for FABP9. The routine cell culture took place 
in tissue culture hood in the Tissue Culture Laboratory. All cell lines were grown and 
maintained as monolayer cultures in RPMI 1640 nutrient medium (Invitrogen, Paisly, 
UK) in 75 cm2 cell culture flask then kept in a humidifier incubator at 37ºC with 5% 
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CO2. RPMI 1640 nutrient medium was supplemented with 10% (vol/vol) foetal calf 
serum, penicillin (100 U/ml) (Bioser, East Sussex, UK), streptomycin (100ug/ml) and L-
glutamine (20mM) (Invitrogen). For LNCaP cells sodium pyruvate (100ug/ml) (Sigma, 
Grillingham, UK) was also added into the culture medium. Cells were fed every 3-4 
days with fresh medium. When cells reached 70-80% confluency, medium was aspirated 
off, and the cells were washed once with phosphate buffer saline (PBS) and passaged in 
1/10 fold. Cells were detached by adding Trypsin 2.5% (v/v) in Versene (T/V) (3ml/75 
cm2 flask or 2ml/25 cm2 flask) and incubated for 3 minutes in humidifier incubator at 
37ºC with 5% CO2.  For deactivation of T/V, double volume of culture medium was 
added.  Cells with medium were centrifuged (91 ×g for 3 minutes) to remove T/V, cell 
pellets were suspended in fresh medium and divided to different flasks. 
 
2.1.3 Transfected cells culture 
 
For transfected cells, Zeocin 100µg/ml (Invitrogen, CA, USA) was added to routine 
selective medium (RSM). All cell culture protocols were same as non-transfected culture 
except using RSM. 
 
2.1.4 Cryopreservation of cells   
 
Healthy cells were detached from tissue culture vessel by Trypsin/Versene, re-suspended 
in PBS, counted and centrifuged at 91 ×g for 3 minutes. Cells was re-susp×ended in 
medium containing 7.5% DMSO (1-1.5×106/ml) to prevent ice crystal formation. Then, 
1ml of cells was pipetted into several cryovial tubes. Cryovials were placed in cryobox, 
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containing isopropanol to decrease the temperature approximately 1ºC/min, and stored at 
-80ºC overnight before transferring to liquid nitrogen for long term storage. 
 
2.2 Evaluating mRNA transcription in cell lines using qPCR 
 
2.2.1 RNA isolation 
Total RNAs of each cell line were isolated using the RNAeasy Mini Kit. When cells 
reached 70-80% confluence, they were harvested and washed with PBS which was 
removed by centrifuging for 3 minutes, 91 ×g as described in section 2.1.1. Then, 350µl 
buffer RLT (containing β-Mercaptoethanol) was added to lyse the cells followed by 
homogenization by centrifuging through PrepEase filter for 1 minute at 1008 ×g and 
precipitated in 70% ethanol. The mixture (700µl) was placed in RNAeasy mini column 
sitting in a 2ml collection tube and centrifuged for 15 seconds in ≥8,000 ×g. The column 
was washed with 700µl buffer RW1 followed by 2 washes with 500µl RPE buffer and 
centrifuged at ≥8,000 ×g for 15 seconds to eliminate any carryover buffer. Then, 30µl of 
RNase free water was added and incubated at room temperature for 1 minute. Finally, 
the total RNA was eluted by centrifuging the column for 1 min at 1008 ×g.  
 
2.2.2 Calculation of RNA concentrations  
The total RNA yield and purity was determined by NanoDrop ND-1000 
spectrophotometer (Labtech, UK). One µl of sample was loaded on the lower 
measurement pedestal. The RNA sample concentration was shown on the screen in 
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ng/µl according to the absorbance at 260 nm the modified Beer-Lambert equation. The 
purity of the sample was also assessed using ratio of absorbance at 260nm and 280nm: a 
ratio of ~ 1.8 was generally accepted as pure for DNA; a ratio of -2.0 was generally 
accepted as pure for RNA. 
 
 
2.2.3 Integrity and quality of total RNAs 
The integrity and quality of total RNAs were determined by an Agilent 2100 bioanalyzer 
using RNA 6000 Nano kit (Agilent Technologies, Germany). First, the electrode was 
decontaminated using electrode cleaner with 350 µl RNaseZAP. Then, one of the wells 
of another electrode cleaner was filled with 350 µl RNase-free water and placed in the 
Agilent 2100 bioanalyzer. Before preparing the gel, all reagents were allowed to 
equilibrate to room temperature for 30 minutes. After that, 550 µl of Agilent RNA 6000 
Nano gel matrix was placed on the top of receptacle of the spin filter. Spin filter was 
placed in the microcentrifuge at 1792 ×g for 10 minutes. Filtered gel (65 µl) was 
aliquoted into 0.5 ml RNase-free microfuge tubes and stored as aliquots at 4ºC.  RNA 
6000 Nano dye concentrate was vortexed and span down for 10 seconds. One µl of RNA 
6000 Nano dye concentrate was added to 65 µl aliquot of filtered gel and vortexed 
thoroughly. Spin tube was centrifuged at 13,000 g for 10 minutes at room temperature. 
Before loading the gel-dye mix, it was allowed to equilibrate to room temperature for 30 
minutes. New RNA Nano chip was placed on the chip priming station. Then, 9 µl of the 
gel-dye mix was loaded into the bottom of the well and the chip priming station was 
closed for 30 seconds. RNA Nano marker (5 µl) was loaded into the ladder well and 
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each well for all samples. One µl of the RNA ladder was pipetted into the well specified 
for ladder and 1 µl of each sample into sample wells, and vortexed gently for 1 minute at 
645 ×g. Within 5 minutes, the chip was carefully placed the receptacle in the Agilent 
2100 bioanalyzer. The 2100 expert software confirmed that chip had been inserted and 
the lid closed by displaying an icon on the screen to start the chip run.  The minimum 
RIN accepted in this study was 9.0. 
 
2.2.4 Polymerase chain reaction (PCR) 
 
PCR is the most common technique used in molecular biology to detect RNA expression 
levels by qualitatively detection of gene expression through creation of complementary 
DNA (cDNA) transcripts from mRNA. Then qPCR is used to quantitatively measure the 
amplification of DNA using fluorescent probes. The gene expression level of all FABPs 
(1-12) in 6 prostate cell lines were investigated. In this study, it was applied to show the 
levels of all FABPs gene expressions in prostate cell lines. 
 
2.2.4.1 PCR primer design 
 
All FABP primers were designed using the PerlPrimer program 
(perlprimer.sourceforge.net/) (Table 2.1). Wherever possible all primers were selected 
according to the following parameters: melting temperature between 57ºC and 63ºC, the 
G+C content between 30-80%, length between 18-22 bp, less than 2ºC difference in 
melting temperature (Tm) between the forward and backward primers. All primers 
including those for β-actin were purchased from Life Technologies Ltd. (Paisly, UK). 
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Table 2. 1: PCR forward and reverse primer sequences for all FABP genes. 
 
 
2.1.1.1  Blast 
 The specificities of all FABPs were confirmed by aligning the working sequence with 
that stored in NCBI data bank, using the nucleotide Blast program 
(http://blast.ncbi.nlm.nih.gov/Blast.cgi?PROGRAM=blastn&PAGE_TYPE=BlastSearch
&LINK_LOC=blasthome).  
  
 
 
Name and 
accession no. 
Forward Tm Reverse Tm 
FABP1 
(P07148) 
CACTTCAAGTTCACCATCACC 61.49 GAACCACTGTCTTGACTTTCTC 61.15 
FABP2 
(P12104) 
AATATTGCGTCCATGTTGCT 60.71 CTACTCAGAAGCCTGAGGC 61.73 
FABP3 
(P05413) 
AAGCCTACCACAATCATCGA 61.30 GTGTCACAATGGACTTGACC 61.20 
FABP4 
(P15090) 
GAAAGAAGTAGGAGTGGGCT 61.23 GTGACTTCGTCAAATTCCTGG 61.54 
FABP5 
(Q01469) 
AAGGAGCTAGGAGTGGGA 61.24 GTAAAGTTGCAGACAGTCTGAG 61.21 
FABP6 
(P51161) 
CATAAAGGAAAGCCTCCCAG 60.42 GTGACGATCTTGAAGTTGCG 61.93 
FABP7 
(O15540) 
TCAAGAAGGAGACAAAGTGG
T 
61.32 CAGGCTAACAACAGACTTACAG 60.96 
FABP8 
(Q9I8L5) 
ATAGAAAGACCAAGAGCATC
GT 
61.58 AGACCTTCTCATAGATTCTGGTG 61.32 
FABP9 
(Q0Z7S8) 
AGGGTTAGTGAAACCGACAG 61.80 GTTATGGTGCTCTTTACTTTCCG 61.85 
FABP12 
(A6NFH5) 
GGAAGGAAATAGCAACAGTG
G 
61.29 CTACACGCTCACCATATAAGC 60.66 
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2.1.1.2 First strand cDNA synthesis 
 
First strand cDNA was synthesized using total RNA isolated from 6 different prostate 
cell lines as described in section 2.2.1. Total RNA (1 µg) was mixed with 1µl of 50µM 
Oligo (dT)2o primer and 2µl of dNTP mixture (10mM each dCTP, dATP, dTTP dGTP, 
at neutral pH). After the volume was adjusted to 13µl with nuclease-free water, the 
mixture was incubated at 65°C for 5 mins and chilled on ice for 1 minute. Then, the 
mixture was mixed with 1µl of 0.1M DTT, 4µl of 5× first strand buffer, 1µl of 
SuperScriptlII reverse transcriptase (200units/µl) and 1µl of RNaseOUT (40units/µl). 
The reaction mixture was incubated at 50ºC for 1 hour, followed by incubation at 70ºC 
for 15mins to inactivate the reaction. The First strand cDNA was used as a template for 
qPCR. 
 
2.1.1.3 Relative real-time PCR 
 
Total RNAs of each cell line using RNAeasy Mini Kit as described 2.2.1 and reverse 
transcribed 1µg of total RNA to cDNA as described in section 2.2.4.3. The real time 
PCR mixtures of β-actin and all FABPs were prepared with 5µl of 2× Brilliant SYBR 
Green qPCR master mix (containing SureStart Taq DNA polymerase, dNTPs mixture, 
MgCL2 and optimized buffer), 1µl of forward primer, 1µl of reverse primer, 1µl of 
cDNA generated by reverse transcription and 2µl of nuclease-free water. After gentle 
mix, the reactions were centrifuged briefly and placed in the real-time PCR 
thermocycler. The real-time PCR program is listed in Table 2.2. 
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Table 2. 2: Real-time PCR program for amplification of short target DNAs  
 Temperature Time 
Step 1 Denaturation 95oC 15 minutes 
Step 2 Denaturation 94oC 14 seconds 
Step 3 Annealing 60oC 30 seconds 
Step 4 Extension 72oC 30 seconds 
Step 5 Plate reading 57oC 15 seconds 
Step 6 Go back to step 2 and repeat 38 cycles 
Step 7 Final extension 72oC 10 minutes 
Step 8 Melting curve 65-95oC 1oC increment for 10 
minutes 
 
2.1.1.4 Relative quantitation analysis  
 
Melting curve analysis was carried out to detect the presence of nonspecific products 
and the primer dimers. The relative fold differences of all FABPs mRNA were obtained 
using the formula listed below: 
Relative fold difference= 2 -∆∆Ct 
 ∆Ct was calculated as the average Ct for the gene of interest minus the average 
Ct for the house keeping gene, β actin. 
 ∆∆Ct was calculated as the ∆Ct of the test sample minus the ∆Ct of the calibrator 
sample. 
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2.2 Evaluating protein expression in cell lines using Western blotting 
 
2.2.1 Isolation of protein extract from cell culture 
 
When cells reached to 80% confluence, they were trypsinized as described in section 
(2.1.1). Cell suspension was centrifuged at 91 ×g for 3 minutes and the supernatant was 
discarded. The cells were lysed with CeLLytic-M reagent (with protease inhibitor) 
(100µl/5×106 cells) and incubated on a roller mixer for 15 minutes at room temperature. 
Then mixture was centrifuged at 11,200 ×g for 20 minutes to pellet the cellular debris. 
The supernatant was harvested into fresh mircocentrifuge tubes.  
 
2.2.2 Bradford assay   
 
The concentration of protein extract was quantified using Bio-Rad protein assay (Bio-
Rad Laboratories GmbH, Munchen, Germany). A standard curve was established by 
measuring the absorbance of a serial dilutions of BSA standards (0.2 – 1.5 mg/ml). 
Protein samples were diluted with PBS and incubated the 1ml 1× dye reagent, which 
filtered through Whatman paper, for 15 minutes. Then, the absorbance was measured at 
595nm using MultiSkan plate reader (BioTeck Instruments, USA). The protein 
concentration was calculated using the established standard curve. 
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2.2.3 Sodium dodecyl sulphate polyacrylamide protein gel electrophoresis 
(SDS-PAGE)   
 
Quantified proteins at concentration of 20µg/10µl were mixed with 10µl of 2× sample 
loading buffer. Then, the mixture was heated at 95ºC on hot plat (Techne, Ori-Block, 
USA) for 10 minutes then chilled on ice for 5 minutes before loaded into the SDS gel. 
Proteins were loaded in 12.5 % Next Gel (Next GelTM 12.5%, Amresco, USA) which 
was prepared by adding 60µl of 10% ammonium persulphate (APS) and 6µl of TEMED 
to 10ml of 12.5% Next Gel. Electrophoresis was performed in a chamber filled with 
500ml of 1× running buffer using Bio-Rad miniprotein system and ran at 150V for 60 
minutes.     
 
2.2.4 Transfer proteins from SDS gel to PVDF membrane 
 
After electrophoresis, proteins were electrophoretically transferred from SDS-PAGE gel 
to PolyVinylidene DiFluoride membrane (PVDF membrane) (Immobilon-P, Transfer 
Membrane, Millipore, USA) using Bio-Rad miniprotein system. PVDF membrane and 
six pieces of Whatman 3MM filter paper cut to the size of 8×9 cm. PVDF membrane 
was soaked in methanol then washed with distilled water and equilibrated in cold 1× 
transfer buffer for 10 minutes. The transfer sandwich was made as follows: the cassette 
was placed into a tray with the black side down, then pre-wet fiber pad, 3 sheets of filter 
paper, gel, membrane, 3 sheets of filter paper and fiber pad were placed on the black 
side of the cassette. After air bubbles were gently removed using glassy roller, the 
cassette was firmly closed. The transfer was performed in the transfer apparatus filled 
with 4ºC 1× transfer buffer at 100V for 1 hour. After transfer, the gel and the membrane 
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were stained with Coomassie blue and 10% Ponceau S, respectively, to assess the 
efficiency of the transfer.  
2.2.5 Immunodetection  
 
To block non-specific bindings, the membrane was incubated with 10ml of 5% blocking 
reagent (TBS-T milk) for 1 hour on a shaker at RT. Then membranes were incubated 
with primary antibody, which was either anti-FABP6 antibody (1:500 Rabbit polyclonal 
FABP6 antibody, Abcam, UK) or anti-FABP9 antibody (1:500 sheep polyclonal FABP9 
antibody, R&D Company) for 1 hour at 4ºC, followed by 3 times wash with 1× TBS-T, 
for 5 minutes each time at room temperature. Then membranes were incubated with 
appropriate secondary antibody conjugated with horseradish peroxidase for 1 hour at 
RT. The secondary antibody was either rabbit anti-mouse antibody (1:10000) for FABP6 
or mouse anti-sheep antibody (1:10000) for FABP9 (Dako, Cambridge, UK).  
Afterwards, membranes were washed 3 times with 1× TBS-T, for 5 minutes each time. 
Then, membranes were incubated with ECL reagents (GE Healthcare, UK) for 5 minutes 
at RT. Finally, protein-antibody complex was visualized by exposure to Kodak XAR-5 
film at room temperature. The intensity of the peak areas of the bands was measured 
using an Alpha Imager 2000 densitometer (Alpha Innotech, Cannock, UK). To correct 
for possible loading discrepancies, the membrane was incubated with β-actin mouse-
antibody (1:50000) for 30 minutes in room temperature, followed by washes as 
previously described. Then membranes were incubated with the secondary antibody 
rabbit anti-mouse (1:10000) for checking β-actin expression. Protein-antibody complex 
was visualized as previously described.    
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2.3 Evaluating Protein expression in tissues using 
immunohistochemistry 
 
2.3.1 Tissue samples and patient data 
 
Human prostate cancer tissues used in this work were obtained from an archival set of 
prostate cancer cases that were held in the archives of the original Pathology Department 
and our Molecular Pathology Laboratory, as described previously (Forootan et al. 2006; 
Forootan et al. 2007; Jing et al. 2002; Zhang et al. 2007). Those patients who were 
originally diagnosed with prostate cancer but died from other causes were excluded from 
this study. All samples were taken from patients with an average age of 67 and 73 years 
who had undergone trans-urethral resection of the prostate (TURP) in the Royal 
Liverpool University Hospital between 1995 and 2001. This study, approved by the 
National Science Ethics Committee, was carried out in accordance with the Medical 
Research Council guidelines (project reference number: Ke; 02/019). All 35 BPH 
samples and 97 adenocarcinomas had been preserved in 10% (v/v) formalin and 
embedded in paraffin wax (Foster, Gosden & Ke 2006). Cases were re-examined 
independently by two qualified pathologists and the carcinomas were classified into 
weakly, moderately and highly malignant tissues according to their combined Gleason 
scores (GS) (Gleason & Mellinger 1974). PSA level were classified into 2 groups low 
(<10ng/ml) and high (≥10ng/ml) according to the initial diagnosis obtained through 
telepath system (Ito et al. 2003).  
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2.3.2 Tissue sections  
 
 Formalin-fixed paraffin-embedded tissues were pre-cooled in a box filled with ice for at 
least 1 hour. Tissue blocks were sectioned at 4µm thickness using microtome 
(MICROM, Oxford, UK). Tissues were placed on labelled Superior Adhesive Slides 
(Apex, Leica, UK), then placed in 37oC oven for overnight to dry out.  
2.3.3 Immunohistochemistry 
 
Immunohistochemistry is a widely used technique to diagnose abnormal cells found in 
malignant lesion (Ramos-Vara 2005). The principle of this technique is to detect 
targeted antigen (or protein) in a cell of tissue section by applying a specific antibody to 
the antigen in biological tissue. In this work, it was used to evaluate the expression of 
different FABP proteins in prostate tissues.   
The resulting 4µm slide-mounted tissues were depariffinised in 2 changes of xylene for 
5 minutes, rehydrated in 2 changes of 100% ethanol for 5 minutes each. To block 
endogenous peroxidase, slides were transferred to 3% hydrogen peroxide (H2O2) in 
methanol for 12 minutes.  Then sections were rinsed in running tap water for 1 minute. 
Antigen retrieval was applied to the sections by incubating all slides in ethylene diamine 
tetra acetic acid (EDTA) solution in the microwave for 15 minutes for FABP9. For 
FABP6, antigen retrieval was performed by microwaving tissues slides in 10 mM 
Sodium Citrate buffer for 15 minutes. Slides were allowed to cool down for 15 minutes, 
then rinsed in running tap water and TBS-T. Slides were transferred to sequenza cassette 
in order to apply the primary antibodies. They were incubated with 100µl primary anti-
FABP9 antibody (1:500 sheep polyclonal FABP9 antibody, R&D Company) or with 
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100µl anti-FAB6 antibody (1:50 rabbit polyclonal FABP6 antibody, Sigma-Aldrich, 
UK) at room temperature for 1 hour and washed with TBS-T 3 times (Table 2.3). Then 
incubated with 100µl rabbit anti-sheep IgG linker or 100µl mouse anti-rabbit IgG linker 
(Vector Laboratories, Burlingame, CA, USA) for 30 minutes followed by 3 washes with 
TBS-T. To detect bound antibodies, 200µl of EnVisionTM FLEX/HRP 
(DakoCytomation, Ely, UK) was applied to the slides and incubated for 1 hour followed 
by 3 washes with TBS-T solution. Sections were incubated with 100µl EnvisionTm 
FLEX DAB+ chromogen mixed with EnvisionTm FLEX substrate (1 drop/ml) 
(Dakocytomation, Ely, UK) to visualize and stained each section for 15minutes and 
rinsed in distilled water for 5 minutes. All sections were counterstained with 
hematoxylin (BWR international, London, UK) for 2 minutes, followed by rinsing in 1% 
acid-alcohol and blue Scott water. Finally, slides were rinsed in 3 changes of xylene and 
mounted with cover slip using DPX mountant (Sigma-Aldrich LTD, UK). 
 
Table 2. 3: Primary antibodies used for immunohistochemistry staining. 
Targeted protein Primary antibody 
                                    
          FABP6 
 
1:50 rabbit polyclonal FABP6 antibody, Sigma-Aldrich, 
UK 
 
FABP9 
 
1:500 sheep polyclonal FABP9 antibody, R&D 
Company 
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2.3.4 Controls for immunohistochemistry 
 
According to the literature and manufacturer recommendations normal kidney tissue and 
breast cancer tissue were used as positive controls for FABP9 and FABP6, respectively.  
For negative control, all staining steps were applied to the same sample except the step 
of adding primary antibody to confirm the efficiency of immunohistochemistry staining 
and the specificity of the antibodies. Isotype controls were not included as all primary 
antibodies used were polyclonal antibodies.   
 
2.3.5 Scoring immunoreactivity 
 
A standard light microscope (×400) was used to evaluate cytoplasmic and nuclear 
expression of FABP6 and FABP9. Immunoreactivity was examined independently by 
two qualified observers. In case of different scoring between 2 observers, a joint 
evaluation needed to re-examine the slides that had different result by using multiple-
headed microscope (Nikon). The slides were scanned with ScanScope (Aperio 
Technologies) image scanner. The intensity of cytoplasmic staining was assessed by 
scoring 10 fields at 40× magnification and was classified into 4 categories: unstained, 
weakly, moderately and strongly stained which were expressed as 0 (-), 1 (+), 2 (++) and 
3 (+++), respectively. Nuclear staining was assessed by the intensity of staining which 
was expressed as 0 (-), 1 (+), 2 (++) and 3 (+++). The differences in scoring categories 
between 2 observers were <5%.  
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2.4 Molecular Biology 
 
2.4.1 RNA Interference: 
 
RNA interference (RNAi) is a natural process that can knock down the expression of 
targeted gene with high specificity. Small or short interfering RNA (siRNA) is the most 
commonly used RNAi tool which is a class of double-stranded RNA molecule, 20-25 
base pairs in length. siRNA is a synthetic RNA interfering with the expression of 
specific genes with complementary nucleotide sequence for validating gene function. 
siRNA tool can also be used for drug targeting in the post-genomic era. Gene 
knockdown by transfection of exogenous siRNA is often unsatisfactory due to that the 
effect of transfection is only transient. Therefore, siRNA sequence is modified 
introducing a short loop between two strands to create a short hairpin RNA (shRNA), 
which can be processed into a functional siRNA by dicer in its usual fashion. 
  
2.4.2 Designing siRNA sequences 
 
Bioinformatics & Research Computing software (Whitehead siRNA selection program) 
was used to choose three different target sequences as shown in Table 2.4. Specificity of 
these sequences to FABP9 was confirmed by Blast search. Sequences were ordered from 
Ambion (by Life technologies, USA). 
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Table 2. 4: FABP9 target and siRNA sequences. Highlighted regions are targeted by 
siRNAs against FABP9 gene. 
Position FABP9 siRNA probes 
 
Sequence 1 
(173-195) 
Sense 5’ CAGGACACUAAGAUCUCCUUU 
mRNA TCCAGGACACTAAGATCTCCTTC 
Antisense 5’ AGGAGAUCUUAGUGUCCUGUU 
 
 
Sequence 2 
(102-124) 
Sense 5’ GGUUAGUGAAACCGACAGUUU 
mRNA    AGGGTTAGTGAAACCGACAGTAA 
Antisense 5’ ACUGUCGGUUUCACUAACCUU 
 
Sequence 3 
(268-290) 
Sense 5’ CUCAAUGAUUCACGUCCAAUU 
mRNA GGCTCAATGATTCACGTCCAAAA 
Antisense 5’ UUGGACGUGAAUCAUUGAGUU 
 
 
 
2.4.3 Transient Transfection 
 
First, 1 × 105 of PC3-M cells was plated into each well in 6-well plates 24 hours prior to 
transfection to reach 30 to 60% confluency. Medium was changed on the day of 
transfection. X-tremeGENE siRNA transfection reagent (Roche, Germany) was diluted 
with serum-free Opti-MEM I Medium (Gibco, Invitrogen, Paisley, UK) (without 
antibiotics or fungicides) and the optimal dilution of transfection reagent per ml was 
47.5ul of Opti-MEM medium plus 2.5ul X-TremeGENE transfection reagent (total 
50ul/ml) added directly into the medium without allowing contact with the walls of 
plastic tubes.  Mix cautiously by pipetting up and down. Also in a separate tube, 
2μg/well of siRNA was diluted with Opti-MEM I medium to a final volume of 100μl. 
After 15 minutes’ incubation in room temperature, diluted siRNA should be combined 
with X-tremeGENE siRNA Transfection Reagent within 5 minutes and mix cautiously 
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by pipetting up and down. Silencer® Negative Control siRNA (Ambion, Inc., USA) was 
also diluted to use as scrambled RNA (control).  The transfection reagent and siRNA 
complex was incubated for 15 minutes at 25 ºC. The complex was then added to certain 
wells. The complex was overlaid drop-wise to the cells, and swirl the wells cautiously to 
ensure distribution over the entire surface.  Dishes were incubated in normal cell culture 
conditions for 48 hours.  Proteins from cells were extracted and the concentration was 
measured by Bradford dye assay in different time points and expression of FABP9 was 
assessed in extracts. The most efficient siRNA was used to design shRNA for stable 
transfection in the most appropriate incubation time. 
 
2.4.4 Designing short hairpin RNA (shRNA) sequences 
 
siRNA Wizard™ Software (InvivoGen, USA) was used to choose the highest 
suppression level for FABP9 (sequence 3). Specificity of these sequences to FABP9 was 
confirmed by Blast searching. Sequences were ordered from Ambion (by Life 
technologies, USA) as shown in Table 2.5. The restriction enzymes that were used are 
HINDIII (AAGCTT) and Acc651 (GGTACC).  
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Table 2. 5: Sequences of shRNAs targeting FABP9 and the negative control. shRNAs 
are capable of DNA integration and consist of two complementary 19–22 bp RNA 
sequences linked by a short loop of 4–11 nt (highlighted) similar to the hairpin found in 
naturally occurring miRNA.  
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2.4.5 Molecular cloning 
 
2.4.5.1  Cloning silencing sequences into vector 
 
psiRNA is specifically designed for cloning (Figure 2.1). Therefore, psiRNA-
h7SKGFPzeo plasmid (InvivoGen, USA) was chosen to perform the vector based 
approach of shRNA.  
 
Figure 2. 1: psiRNA-h7SK-GFPzeo vector map. 
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2.4.5.2  Annealing sense and anti-sense oligos  
Forward and reverse oligonucleotides were dissolved at a concentration of 100μM (stock 
concentration), and were more diluted to 25μM (working concentration). Reaction was 
prepared by mixing the components shown in Table 2.6. The prepared reaction was 
incubated for 2 minutes at 80°C then stopped the heating and maintained in water bath 
till the temperature reached to 35°C. Annealed inserts were stored at -20°C. 
Table 2. 6: Annealing reaction. 
Forward oligonucleotide (25μM) 2μl 
Reverse oligonucleotide (25μM) 2μl 
NaCl (0.5M) 6μl 
H2O to a final volume of 30μl 
 
2.4.5.3  Competent bacteria cells preparation 
 
The most compatible strain with hairpin harbouring plasmids is E. coli GT116 strain. 
Therefore, in this preparation E. coli GT116 was used for transformation. First E. coli 
GT116 was kept on ice for 5 minutes, then 1ml of re-constitutive solution was added and 
kept on ice for 5 minutes. A stock solution of E. coli GT116 was prepared by incubating 
25ml of LB medium (without antibiotic) with 25-100µl of re-constitutive cells. 
Overnight culture was aliquot in 20% glycerol, flash freezing in LN and stored in -80°C. 
E. coli GT116 glycerol stock was streaked on a LB-agar plate and incubated at 37oC. 
Then, a single colony was inoculated into 10ml of LB broth and incubated overnight at 
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37oC with shaking at 6 ×g. On the following day, 1ml of overnight grown bacteria was 
transferred into 100ml SOB medium containing 1ml 2M magnesium salt and incubated 
for 90 minutes at 37oC with shaking at 6 ×g until the OD550 reached 0.4. After that, the 
culture solution was divided into 8 universals (12.5ml/universal) and placed on ice to 
cool down for 10 minutes, then centrifuged at 4oC in 2000 ×g for 10 minutes.  The 
supernatants were discarded and the bacterial cell pellets were re-suspended in 8.25ml of 
pre-cooled RF1 buffer (100mM KCL, 50mM MgCL2. 4H2O and 15% v\v glycerol, 
PH6.8) and placed on ice for 10 minutes, then centrifuged at 2500×g for 10 minutes. The 
bacterial cell pellets were re-suspended in 2ml of RF2 (10mM MOPS, 10mM KCL, 
75mM CaCl2.2H2O and 15% v/v glycerol, PH6.8). Finally, E. coli GT116 bacteria 
solution was dispensed into 1ml cryovials, flash frozen in liquid nitrogen and stored at -
80oC.    
2.4.5.4  Double digestion of plasmid DNA 
 
To prepare double digestion of plasmid, psiRNA plasmid was thawed on ice, the 
following components was mixed in order to prepare digestion reaction (Table 2.7):  
Table 2. 7: Double digestion reaction. 
psiRNA-h7SK-GFPzeo plasmid (1μg) 2μl 
Enzyme buffer 2μl 
HindIII, restriction enzyme 1μl 
Acc651, restriction enzyme 1μl 
H2O to final volume of 20μl 
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The digestion reaction was incubated for 1 hour at 37oC water bath then transferred to 
68oC for 10 minutes to deactivate enzymes. Agarose gel analysis (0.8%) was used to 
validate enzyme digestion. Wizard SV Gel and PCR Clean-Up system (Promega, WI, 
USA) was used to purify the digested plasmid. After running DNA samples on the gel, 
the digested plasmid band was cut with sterile blade and transferred to sterile 
microcentrifuge tube and Membrane Binding Solution (10μl/10μg of gel) was added. 
Reaction was mixed by vortex and incubated for 10 minutes at 50-56oC. Mixed reaction 
was loaded in Wizard SV Mini columns and centrifuged for 1 minute in 10,000×g 
followed by two steps washing with 700 and 500μl of Membrane Wash Solution, which 
was removed by 5 minutes centrifuging at 10,000×g. Nuclease-free water (30μl) was 
added directly to the centre of column followed by 1-minute centrifugation at 21952 ×g . 
Finally, eluted DNA (plasmid) was used for ligation and kept at -20oC.     
 
2.4.5.5  Ligation shRNA insert into psiRNA 
 
Ligation reaction was prepared by mixing digested psiRNA-h7SK-GFPzeo plasmid, 
annealed shRNA (FABP9 and negative control), T4 DNA ligase, 10× ligation buffer and 
H2O according to volume shown in Table 2.8. The reaction was incubated at 16
oC 
overnight.  
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Table 2. 8: Ligation reaction. 
 
 
 
 
 
 
 
 
 
2.4.5.6 Transformation 
 
A cryovial of E. coli GT116 competent cells was thawed on ice. No more than 50ng of 
plasmid DNA (10μl) of ligation mixture was added to 200μl of competent cells, mixed 
gently and placed on ice for 30 minutes. Another tube containing competent cells only 
was used as control. The reaction was incubated at 42oC water bath for 90 seconds then 
placed on ice for further 2 minutes. Then 800μl of SOC (2% w/v bactotryptone, 0.5% 
w/v yeast extract, 10mM NaCI2, 10mM MgCI2, 10mM MgSO4, 2.5mM KCI, 20mM 
glucose) was added and incubated for 1 hour at 37oC in a shaking incubator at 225×g. 
Transformed bacteria (200μl) was plated onto agar-plate containing 100μg/ml Zeocin 
and incubated at 37oC overnight.  
 
 
 
 
Digested psiRNA-h7SK-GFPzeo plasmid 1μl (100ng) 
Annealed shRNA  1μl 
T4 DNA ligase 1μl 
10× ligation buffer 2μl 
H2O to a final volume of 20μl 
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2.4.5.7  Transformation efficiency  
 
Transformation efficiency is calculated by dividing the number of successful colonies by 
the amount of DNA (per μg) used during transformation preparation. Transformation 
efficiency is affected by many factors such as procedure of transformation, plasmid size, 
cell genotype etc.  
 
2.4.5.8  Plasmid DNA isolation 
 
To isolate DNA containing shRNA sequence, colonies were picked from the plate and 
grown in LB broth containing Zeocin overnight at 37oC shaker. Plasmids were isolated 
and purified using QIAGEN plasmid preparation kits. Mini-preparation kit (QIAGEN, 
USA) was used for preparation of up to 20μg plasmid DNA. Preparation of more than 
20μg, QIAGEN plasmid midi-preparation kit (QIAGEN, USA) was used.  
2.4.5.8.1 Mini-preparation DNA extraction 
 
The overnight-cultured bacteria (5ml) in LB medium containing Zeocin were harvested 
by centrifuging at 6800×g for 3 minutes at room temperature. The cell pellets were re-
suspended in 250μl buffer P1 (50mM Tris-HCI PH8.0, 10mM EDTA and 100μg/ml 
RNaseA) in 1.5ml micro-centrifuge tubes and mixed by vortex. Then, 250μl of cell lysis 
buffer P2 (200mM NaOH and 1% w/v SDS) and was mixed by inverting several time 
followed by adding 350μl of neutralization buffer N3 (4.2M Gu-HCI, 0.9M Potassium 
acetate PH4.8) and mixed gently by inverting tubes several times. The mixture was 
centrifuged at 13,000×g for 10 minutes and the supernatant which contained DNA was 
loaded into the mini-prep spin column. The column was centrifuged at 13,000×g for 1 
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minute and washed by buffer PB (500μl) followed by centrifugation for 1 minute and the 
flow through was discarded. Then, the column washed by adding 750μl of buffer PE 
followed by centrifugation at 13,000×g for 1 minute and the flow through was discarded. 
To remove residual wash buffer, the column was centrifuged for an additional 1 minute. 
The column was placed in clean micro-centrifuge tube and plasmid DNA was eluted by 
adding 30μl of buffer EB and incubated for 1 minute at room temperature followed by 1-
minute centrifugation at full speed (18928 ×g).        
 
2.4.5.8.2 Midi-preparation DNA extraction 
 
The overnight-cultured bacteria (200ml) were centrifuged for 15 minutes at 6800×g at 
4oC and the supernatant was discarded. The pellets were re-suspended in 4ml buffer P1 
in PP bottles by using vortex. The bacteria cells were lysed by adding 4ml of buffer P2 
and mixed gently by inverting the bottles 4-6 times and incubated for 5 minutes at room 
temperature. Then, buffer P3 (4ml) was added and mixed gently by inverting several 
time and placed on ice for 5 minutes. The mixture was centrifuged at 16,000×g for 30 
minutes at 11oC. After transferring to clean tube, plasmid DNA was further centrifuged 
for 30 minutes at 20,000×g, 11oC. The supernatant was loaded into a Qiagen-tip 100 and 
equilibrated by adding 4ml of equilibration buffer QBT and allowed to empty by gravity 
flow. The column was washed twice with 10ml of buffer QC and plasmid DNA eluted 
by adding 5ml of elution buffer QF. Then, 3ml of isopropanol was added to the eluted 
DNA and mixed followed by 30 minutes’ centrifugation at 11,000×g, 4oC. The 
supernatant was carefully removed and DNA pellet was washed by adding 2ml of 70% 
alcohol and centrifuged at 20,000×g for 15 minutes. The DNA pellet was air-dried for 
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10 minutes then dissolved in 200μl of nuclease-free water. The quality and concentration 
of DNA was assessed by NanoDrop spectrophotometer and the isolated plasmid DNA 
was kept at -20oC.  
2.4.5.8.3 Agarose gel analysis 
 
After DNA isolation, the presence of shRNA inserts in the plasmid is assessed by few 
techniques. One is to digest the plasmid and apply the digested DNA to agarose gel 
electrophoresis and visualized the presence of insertion. Here, the plasmid DNA was 
double digested (2.5.1.5.4). The agarose concentration of the gel was 0.8% according to 
DNA size. Then a 0.8% agarose gel was prepared in 200ml of 0.5× TBE buffer using 
microwave to dissolve the agarose until the temperature reached to 50oC. When the 
temperature reached to 50ºC, safe view (Nucleic Acid Stain) (NBS Biological Ltd., 
Cambridgeshire, UK) was added to agarose mixture for visualization, then poured in 
cassette and placed at 4oC to solidify. Samples were loaded in the gel and undigested 
plasmid was used as a control. The gel was run at 80v in 0.5×TBE buffer for 1 hour and 
UV light was used for visualization digested bands. 
  
2.4.5.8.4 Sequencing analysis  
 
Plasmid psiRNA-h7SK-GFPzeo sequences were sent to Beckman Coulter Genomics, 
UK for sequencing. Plasmid primers that were used are: 
[(forward):5’CGATAAGTAACTTGACCTAAGTG3’; 
(reverse):5’GCGTTACTATGGGAACATAC3’]. Specificity of these sequences was 
confirmed by Genbank Blast search. 
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2.4.6 Stable Transfection 
 
1×105 of PC3-M cells were seeded per well in 6-well plates 24 hours prior to 
transfection to allow them to reach the confluency of 30-60%.  PC3-M was stably 
transfected with vectors containing different FABP9 shRNAs using X-tremeGENE HP 
DNA Transfection Reagent (Roche, Germany). 1μl X-tremeGENE HP DNA 
Transfection Reagent was diluted in 99μl of Opti-MEM I medium (Gibco, Invitrogen, 
Paisley, UK) to a final volume of 100μl. 4μg of psiRNA with inserted shRNA was 
added to the diluted Opti-MEM I medium and mixed gently then incubated at room 
temperature for 15 minutes. In a separate transfection, a vector containing scrambled 
RNA was used as a control. The mixture was added dropwise to the wells of 6-well 
plates and distributed by rocking the plate back and forth. The 6-well plates were 
incubated in standard growth conditions for 48 hours. Then, the medium was replaced 
with those containing ZeocinTM (100μg/ml) (Invitrogen, by Life technology, USA) and 
changed every three days until control transfection cells died out and healthy cell clones 
had formed in the plate (3-4 weeks). The surviving transfected cells were distributed into 
9cm cell culture plates with selective medium ZeocinTM for two weeks. 
 
2.4.6.1 Ring cloning of transfected cells 
Ring cloning technique was used to isolate five single colonies to establish FABP9-
supressed PC3-M transfectants and the level of FABP9 in these transfectants was 
measured by Western blot analysis as shown in section (2.3). Single colonies were 
selected and isolated by using sterilized 8×8 mm cloning rings (Sigma-Aldrich LTD, 
UK), forceps and Dow Corning® high-vacuum silicone (Sigma-Aldrich LTD, UK). 
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Using forceps, cloning rings were dipped in silicon grease and placed in over the colony. 
The small amount of grease used was to form a watertight seal around the colony and to 
stick to the plate. Then, 100μl of 2.5% trypsin/versine (v/v) was added to the colony and 
incubated for 4 minutes to detach the cells. Equal amount of routine cell culture medium 
was added to deactivate the trypsin and centrifuged for 3 minutes at 91 ×g.  The pellets 
were re-suspended in 1ml selective medium and grown in 24-well plate in normal cell 
culture conditions.    
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2.5 In-vitro assays 
 
2.5.1 MTT cell proliferation assay 
 
The increased proliferation is one of cancer cell characteristics which can predict the 
potential of tumorigenicity and metastasis. Therefore, MTT (3-(4, 5-dimethylthiazolyl-
2)-2, 5-diphenyltetrazolium bromide) cell proliferation assay was used to measure the 
cell proliferation rate. The linear relationship between cell number and signal production 
was established for each cell line to allow an accurate quantification of changes in the 
rate of cell proliferation.  
 
2.5.1.1 Growth curve preparation 
 
MTT (3-(4, 5-dimethylthiazl-2-yl)-2, 5-diphenylterazolium bromide) is a yellow 
chemical reagent has the ability to enter the mitochondria of cells and converted into 
blue dye by oxidative enzymes forming so-called formazan crystal in cell cytoplasm. 
Formazan crystals are dissolved by adding DMSO and the intensity of blue solution is 
directly proportional to the number of the cells.  Optical density (OD) of dye will be 
measured at 570nm. 
A standard curve was established for each cell line by preparing a serial dilution for both 
parental cells and transfectants at a density of: 6.25×103/ml, 1.25×104/ml, 2.5×104/ml, 
5×104/ml, 1×105/ml, 2.5×105/ml, 5×105/ml cells per well in 96-well round bottom plate 
in triplicate. Then, cell suspension containing 6.25×104/ml was prepared and 1.25×104 
(200µl) and incubated in 96-well plate in triplicate to measure proliferation activity of 
each cell line. After that, 50µl of MTT solution was added to each well and incubated at 
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37oC, 5% CO2 and 95% humidity. For the OD of dye will be measured at 570nm. A 
standard curve was established between the optical density of formazan and the number 
of cells. From this standard curve the cell viability of each cell line can determined.  
 
2.5.1.2   Cell number determination 
 
Parental cell and transfectants were seeded in 96-well plate in culture medium in 
triplicate at 5,000 cells per well at day zero. A MTT solution was prepared by a 
concentration of 5mg/ml in PBS. On days 1-6, 50µl of MTT solution was added to each 
well and incubated for 4 hours at 37oC, 5% CO2 and 95% humidity. Then, 200µl of 
medium was removed from each well and 200µl of DMSO was added and incubated for 
10 minutes. The optical density of the cell proliferation colour was measured by 
Multiscan plate reader at 570nm every day for 6 days. The cell viability was calculated 
corresponding to the standard curve.  
 
2.5.2 Invasion Assay 
 
Tumor invasion and metastasis are hallmarks of tumour malignancy. The Boyden 
chamber system has been used to assess different invasion aspects of cancer cells. The 
principal is that cancer cells migrate along a chemoattractant gradient from an upper 
compartment into the lower compartment. Many factors can affect the results such as 
cells number, the duration of the assay and measurement methods. The BD BioCoatTM 
Growth Factor Reduced (GFR) MatrigelTM Invasion Chamber (BD Biosciences, USA) is 
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a solubilized tissue basement membrane preparation, contains collagen type IV, laminin, 
growth factor, heparin sulphate proteoglycan and entactin.  
PC3-M cells and transfectants were cultured until 70-80% confluent. Twenty-four hours 
prior to performing the assay, cells were starved (grow in serum free medium) at 5×104 
cells/ml. In the meantime, the invasion chambers were brought out and allowed to come 
to room temperature and dehydrated by adding 0.5ml of warm medium and incubated in 
a humidified incubator at 37oC, 5% CO2 for 2 hours. Then, medium was removed 
carefully without disturbing the GFR Matrigel layer. Cells (2.5×104) were seeded in the 
upper compartment of chambers in 500µl of growth medium while 1ml of routine 
medium was loaded in lower compartments. As a negative control, serum free medium 
was placed in the lower compartments. All cell lines were set as triplicate and assays 
was incubated at 37oC, 5% CO2. After 24 hours, cotton swabs were used to remove the 
remained cells in upper compartments and washed twice with PBS. Finally, cells 
migrated to the lower side were fixed, stained with 2% crystal violet for 10 minutes and 
washed with water several times and left to dry at 37oC. The number of invading cells 
was counted using a light microscope (Leitz, Labovet, Luton, UK) at 124× 
magnification. Olympus digital camera (Olympus C-4040) was used to take 
photographs.   
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Figure 2. 2: Principle of Invasion assay performed in chamber with 8µm pore size 
which coated with Matrigel matrix. 
 
2.5.3 Soft Agar Assay 
 
Anchorage-independent growth is considered to be a hallmark of cell transformation and 
carcinogenesis. Soft agar colony formation assay is one of the most common in vitro 
techniques for malignant transformation in cells to monitor anchorage-independent 
growth, which measure proliferation in semisolid matrices. Therefore, this assay was 
designed in order to examine the tumorigenicity of each cell line in anchorage-
independent environment.  
To perform the assay, 6-well plates were pre-coated with 2ml of 2% (w/v) low melting 
agarose gel in routine and selective culture medium with 10% FCS and the mixture 
solidified in refrigerator at 4ºC for 20 minutes. Parental PC3-M, PC3M-FABP9-siM and 
PC3M-FABP9-siH cells were routinely grown to 70-80% confluency, detached, 
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harvested and adjusted with routine medium to 5000 cells/well. Then, 1ml of cells 
suspension of each cell line (5000 cells/ml) was mixed with 1ml of 1% low melting 
point agarose gel and placed on top of the pre-coated wells. Complexes were placed in 
4ºC for 10 minutes for solidification. Then, the 6-well plates were placed in the incubator 
at 37 ºC, 5% CO2 for 4 weeks. In the meantime, cells were feed with routine culture 
medium 200ul/well once a week. At the end of assay, colonies were stained by adding 
0.5ml of 2% MTT (5mg/ml) (3-(4, 5-dimethylthiazl-2-yl)-2, 5-diphenylterazolium 
bromide) then incubated at 37ºC, 5% CO2 for 4 hours. Colonies larger than 150um were 
counted using Gel Count (Oxford Optronix, UK). 
2.5.4 Wound healing assay  
  
Wound healing assay is one of the most common in vitro techniques to study cell 
migration. This method is based on the observation that so-called scratch on a confluent 
cell monolayer. After creating a scratch, the cells on the edge of the artificial gap will 
migrate toward the gap to close the scratch until cell-cell contacts are observed. To 
determine the rate of cell migration, images are captured at the beginning and regular 
intervals during cell migration. Captured images are compared using Image J to 
determine migration rate. 
Parental PC3-M cells, PC3M-FABP9-siM and PC3M-FABP9-siH were seeded in 6-well 
plate and cultured until 75-80% confluent. Then, yellow pipette tip was used to make a 
straight scratch, creating a wound. The pipette tip was kept under an angle of around 30 
degrees to keep the scratch width limited. The positions were selected to take photos and 
3 images were taken per well at 0 hour. After that, the migration was monitored by 
taking images at 6 hours, 12 hours and 24 hours.   
Materials and Methods 
104 | P a g e  
 
2.6 Statistical analysis 
 
In all statistical analysis, if the p value is less than 0.05 (Two-sided test) the results were 
regarded as significant.  
2.6.1 Statistical Package for Social Sciences (SPSS) 
 
The analysis was performed using the Statistical Package for Social Sciences (SPSS) 
version 20 (SPSS Inc., Chicago, IL., USA). 
2.6.2  Chi-square (χ2) 
 
Chi-square (χ2) test was used to assess whether the differences between the expected 
frequencies and the observed frequencies is significant or not. Correlation between 
FABP6 and FABP9 expression and the benign and malignant prostate tissues were 
assessed by χ2 test. 
 
2.6.3 Survival analysis 
 
2.6.3.1 Kaplan-Meier curve 
 
Kaplan Meier plots were used to separate survival times of patients with differentially 
stained samples for individual factors. In this study Kaplan Meier plots were used to 
assess the correlation between survival and expression of FABP6, FABP9, Gleason 
score, PSA level, AR level.   
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2.6.3.2 Log Rank test  
 
The significance association between survival time and expression of FABP6 or FABP9 
was assessed by Log Rank test.  It is a nonparametric test and appropriate to use when 
the data are right skewed and censored (technically, the censoring must be non-
informative). 
2.6.3.3 Mann-Whitney U test  
 
Man-Whitney U test is a non-parametric test that is used to compare two sample mean 
ranks, when the variable is either ordinal or continuous, but not normally distributed. 
The correlation between the expression of FABP9 and different markers was assessed 
using Box plot analysis and Mann-Whitney U test.  
2.6.3.4 Student t-test  
 
Student’s t-test was used to evaluate the significant difference in average between two 
groups and is most commonly applied when the test statistic would follow a normal 
distribution. In this study, Student’s t-test was used to compare any observed difference 
between experimental and control groups in Western blot, proliferation assay, invasion 
assay, soft agar assay. A value of p ≤ 0.05 was used to define the statistical significance. 
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3. Results 
3.1 Measurements of levels of FABP mRNAs in 
prostate cell lines 
 
3.1.1 The quality and integrity of the total RNAs 
 
The relative levels of FABPs levels in six different cell lines were measured by 
quantitative RT-PCR. Total RNAs for each cell line were isolated and purified by 
RNAeasy Mini column. The total RNA yield and purity was determined by NanoDrop 
ND-1000 spectrophotometer. The purity of the sample was also assessed using ratio of 
absorbance at 260/280nm.  The optimal rang of ratio were:                                                                                                                     
-260/280 ratio: 1.8-2.0 was generally accepted as pure DNA.                                                                           
-260/280 ratio: 2.0-2.1 was generally accepted as pure RNA. 
The quality and integrity of the mRNA were assessed using RNA 6000 Nano LabChip 
kit on Agilent 2100 Bio-analyzer because poor quality RNA can affect subsequent 
reactions leading to erroneous results in the expression results. The 2100 Expert 
Software and visual output was used to analyze the results to confirm that the total RNA 
was in high quality by showing two clear bands representing both rRNA 18S and 28S 
sub-units as shown in Figure 3.1. The high RNA integrity number (RIN) of each 
isolated RNA (at least 9.0 out of 10) showed that the total RNA was intact and no 
degradation was observed (Figure 3.2).  
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Figure 3. 1: The quality and quantification of total RNA were assessed using the RNA 
6000 Nano LabChip on Agilent 2100 bioanalyzer.                                                                                          
The electrophernograms of the gel-like images of mRNAs from 6 cell lines and from the 
RNA ladder (marker).  The gel electropherogram images for different benign and 
malignant cell lines were shown in this figure.  
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Figure 3. 2: The quality and quantification of total RNA were assessed using the RNA 
6000 Nano LabChip on Agilent 2100 bioanalyzer.                                                                               
The double peaks representing both rRNA 18S and 28S sub-unites and the RNA 
integrity numbers (RIN) of the samples from different cell lines. The fluorescence plots 
with two peaks of 18S and 28S ribosomal RNAs of each sample were shown in panel B. 
The qualities of RNAs were presented by RINs which were calculated from the plots. 
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3.1.2 Relative levels of mRNAs of all FABPs in prostate cells 
 
Messenger RNAs of 10 different FABPs were isolated, their relative levels were 
analysed by quantitative RT-PCR between the benign PNT-2 cells, and compared and 
the 5 malignant prostate cell lines (LNCaP, 22RV-1, Du145, PC-3 and PC3-M) and the 
results are shown in Figure 3.3.  
3.1.2.1 Expression Pattern of FABP1, FABP2, FABP3, FABP7 and 
FABP8 
 
Assessing transcription profiles between the benign and malignant cells showed that 
FABP1, FABP2, FABP3, FABP7 and FABP8 exhibited no unified patterns in mRNA 
levels between benign and malignant cell lines. Thus, no clear differences in their 
mRNA levels were identified when compared with those in the benign cells. Therefore, 
FABP1, 2, 3, 7 and 8 were excluded from any further studies.  
3.1.2.2 FABP4 
 
Assessing transcription profiles between the benign and malignant cells showed that 
FABP4 mRNA exhibited clearly higher level in 2 of the 5 malignant prostate cells PC-3 
and PC3-M cells, but its expression in other prostate cells including benign PNT-2 cells 
was not detectable. The expression of FABP4 was one of the predominant FABP family 
members in prostate cells when compared with all of the other FABPs.  
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3.1.2.3 FABP5 
 
Expression level of FABP5 was elevated significantly in all of prostate cancer cell lines 
LNCaP, 22RV-1, PC-3 and PC3-M when compared with the benign PNT-2 cells. PC-3 
and PC3-M, examples of highly aggressive prostate cancer cells, showed higher levels 
of FABP5 when compared with the other prostate cancer cell lines as shown in our 
group previous work (Jing et al. 2000).   
3.1.2.4 FABP6 
  
RT-PCR analysis of 6 different prostate cell lines showed a marked level of FABP6 
mRNA expression in malignant cells compared with no expression in the benign cells 
PNT-2. Notably, FABP6 expression was significantly higher in prostate cancer cells 
than those detected in the benign cells PNT-2. In contrast, the expression of FABP6 in 
metastatic to brain was lower than the level obtained with other malignant cells. 
Therefore, FABP6 was found to be another predominant FABP family members in 
prostate cells when compared with all of the other FABPs at mRNA level.  
3.1.2.5 FABP9 
 
Gene expression of FABP9 in malignant cell lines was 5-47 fold higher than that 
detected in the benign PNT-2 cells.  PC-3 and PC3-M, examples of highly aggressive 
prostate cancer cells, showed higher levels of FABP9 when compared with the other 
prostate cancer cell lines. Thus, FABP9 was found to be one of the highly expressed 
FABP members in prostate carcinoma cell lines. 
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3.1.2.6 FABP12 
 
FABP12 mRNA level in prostate cancer cells was 3-105 fold higher than that in the 
benign PNT-2 cells. Notably, benign PNT-2 cells showed the lowest expression of 
FABP12 amongst prostate cell lines.    
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Figure 3. 3 : Quantitative PCR analysis of relative levels of FABP mRNAs in benign 
and malignant prostate epithelial cells.                                                                                                                  
Benign cell line PNT-2, weakly malignant cell line LNCaP, moderately malignant cell 
line 22RV-1 and highly malignant cell lines Du145, PC-3 and PC3-M were cultured to 
80% confluence and harvested for mRNA extraction. 
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3.2   Expression of FABP6 and FABP9 in prostate cells 
at the protein level 
 
Amongst the differentially expressed FABPs, FABP4 was released from adipocytes, 
implicated in obesity (Hotamisligil et al. 1996) and its possible involvement in the 
malignant progression of prostate cancer has been investigated previously (Uehara et al. 
2014). The crucial role of FABP5 in promoting tumorigenicity and metastasis of prostate 
cancer have been characterized by our group. FABP12 is the most recent member, it 
may play an important role in prostate cancer and thus a separate investigation has been 
conducted in another project to study FABP12 by a member of our team. Therefore, the 
main work was focused on the role of FABP6 and FABP9 in prostate cancer. 
3.2.1 Expression of FABP6 protein 
 
The Western result analysis of FABP6 in prostate cell lines is shown in Figure 3.4. A 
single FABP6 band of 14 kDa was detected in positive control breast cancer MCF7 cell 
line, benign cell line PNT-2, weakly malignant cell line LNCaP, moderately malignant 
cell line 22RV-1 and highly malignant cell lines Du145, PC-3 and PC3M (Figure 3.4A). 
When the densitometric level of FABP6 in PNT-2 is set at 1, the levels in weakly 
malignant LNCaP, moderate malignant 22RV-1 and highly malignant Du145, PC-3 and 
PC3-M were 0.86±0.15, 0.82±0.30, 2.15±0.04, 0.63±0.01 and 0.49±0.28, respectively. 
Quantitative analysis showed that the level of FABP6 in highly malignant Du145 cells 
was more than 2 times than that in the benign PNT-2 cells (Student’s t-test, p = 0.01). 
The levels of FABP6 in low malignant LNCaP cells, moderately malignant 22RV-1 
cells, highly malignant PC-3 and PC3-M cells were lower than that in PNT-2 cells 
(Figure 3.4B) but the differences were not significant (Student’s t-test, p>0.05). 
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Therefore, FABP6 appear to be overexpressed in at least one of the highly malignant 
cells lines.   
 
3.2.2 Expression level of FABP9 at protein level 
 
Western blots analysis showed that FABP9 protein was highly expressed in 2 (PC-3 and 
PC3-M) of the 5 malignant cell lines, but its expression in other prostate cells including 
benign PNT-2 cells was not detectable (Figure 3.5A). When the level of FABP9 was set 
at 1 in PC-3, the level in the most aggressive cell line PC3-M was 1.2±0.04. Thus the 
level of FABP9 in the highly malignant cells PC3-M was 20% significantly higher than 
that in PC-3 (Student’s t-test, p= 0.006) (Figure 3.5B).  
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Figure 3. 4: Expression of FABP6 in benign and malignant prostate cells.                              
A), Western blot analysis of FABP6 in benign and malignant prostate cells. B), relative 
levels of FABP6 in different cell lines. The level of FABP6 in benign PNT-2 cells was 
set at 1.0; levels in other cell lines were obtained by relating to that in PNT-2. The 
results were obtained from 3 separate experiments (mean ± SD).  
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Figure 3. 5:  Expression of FABP9 in benign and malignant prostate cells.                               
A), Western blot analysis of FABP9 in benign and malignant prostate cells. B), relative 
levels of FABP9 in different cell lines. Since the expression in PNT-2, LNCaP, 22RV-1 
and Du145 is not detectable, their levels were set as “0”. When the level in PC-3 cells 
was set at 1.0, the level in PC3-M cells was obtained by relating to that in PC-3.  The 
results were obtained from 3 separate experiments (mean ± SD).  
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3.3   Expression of FABP6 and FABP9 in prostate 
tissues 
 
The expressions status of FABP6 or FABP9 in 133 prostate tissue sections, including 36 
BPH and 97 carcinoma tissues, was detected by immunohistological staining and 
representative staining patterns are shown in Figure 3.7 and Figure 3.8. Some cases 
were excluded from the study because of technical or other reasons, and the exact 
numbers of cases that were used in this study presented in Table 3.1 and Table 3.2 is 
summarised in Figure 3.6.  
 
 
 
 
 
 
 
Figure 3. 6: Summary of patient tissue numbers used in this study for both FABP6 and 
FABP9.  
 
 
 
133 Prostate cancer tissues 
97 Carcinoma 
tissues 
36 BPH tissues 
33 BPH for 
FABP6 
36 BPH for 
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3.3.1 Expression of FABP6 in prostate tissues 
 
For anti-FABP6, staining was observed only in the nucleus of the cells (Table 3.1) and 
no cytoplasmic staining was seen.   Nuclear staining was observed in all 33 BPH tissues 
(100%); 3 tissues (9%) stained weakly, 25 tissues (76%) stained moderately, and 5 
tissues (15%) stained strongly (Figure 3.7). Among the 92 adenocarcinomas, 28 tissues 
(30%) were unstained, 11 tissues (12%) stained weakly, 23 tissues (25%) stained 
moderately and 30 tissues (33%) stained strongly. Although FABP6 was detected in the 
nucleus of the cells, the staining intensities between BPH and carcinoma tissues were 
not significantly different (χ2 test, p > 0.05).   
   
3.3.2 Expression of FABP9 in prostate tissues 
 
The expression of FABP9 in both BPH and carcinoma tissues was detected in the 
cytoplasm (Figure 3.8) and no nuclear staining was seen, the results are shown in Table 
3.2. Among 36 BPH cases 25 (70%) were unstained and 11 (30%) stained weakly. 
Among 86 adenocarcinomas, staining was weak in 31 (36%), moderate in 39 (45%) and 
strong in 16 (19%) cases (Table 3.2). No nuclear staining was observed in any BPH and 
carcinoma samples. Comparing the FABP9 expression between BPH and carcinomas, 
the staining intensity in carcinoma tissues was significantly stronger (χ2 test, p<0.0001). 
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Figure 3. 7: Examples of immunohistochemical detection of FABP6 in benign and 
malignant prostate tissues.                                                                                                                                                                  
Following the manufacturer instruction, breast cancer tissue was used as positive 
controls for FABP6 (x100). Carcinomas were divided into three categories according to 
their combined Gleason scores (GS): weakly malignant (or GS ≤5), moderately (or GS 
6-7) and high malignant (or GS 8-10) tissues.    
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FABP6 Nuclear stain intensities a No. of cases 
Tissues 0 + ++ +++  
BPH 0 3 25 5 33b 
Carcinomas 
(Total) 
28 11 23 30 92b 
GSc ≤5 14 0 6 3 23 
GSc 6-7 10 6 10 10 35 
GSc 8-10 5 5 7 17 34 
a Staining was observed only in the nucleus of the cells. b Total BPH were 36 and total 
carcinomas were 97, but some cases were excluded because of technical reasons. c 
Combined Gleason scores. 
 
 
 
 
 
 
 
 
 
Table 3. 1: Immunohistological stains of tissues with antibody against FABP6. 
Results 
122 | P a g e  
 
 
 
 
  
 
 
Figure 3. 8: Examples of immunohistological detection of FABP9 in benign and 
malignant prostate tissues.                                                                                                                                                          
Following the manufacturer instruction, normal kidney tissue was used as positive 
controls for FABP9 (x100). Carcinomas were divided into three categories according to 
their combined Gleason scores (GS): weakly malignant (or GS ≤5), moderately (or GS 
6-7) and high malignant (or GS 8-10) tissues.    
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Table 3. 2: Expression status of FABP9 in benign and malignant prostate tissues. 
a Staining was observed only in the cytoplasm of the cells. b Total carcinomas were 97, 
but some cases were excluded because of technical reasons. c Combined Gleason scores. 
 
 
 
 
 
 
 
FABP9 Cytoplasmic stain intensities a No. of cases 
Tissues 0 + ++ +++  
BPH 25 11 0 0 36 
Carcinomas 
(Total) 
0 31 39 16 86b 
GS c ≤5 0 22 6 0 28 
GS c 6-7 0 7 13 5 25 
GS c 8-10 0 2 20 11 33 
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3.4  Correlation of FABP6 and FABP9 expression to 
Gleason Scores 
 
According to their GS, carcinomas were divided into 3 groups: low (GS ≤5), moderate 
(GS 6-7) and high malignant (GS 8-10), as shown in Table 3.1 and Table 3.2. 
Of the 23 weakly malignant carcinoma tissues, 14 (60%) no staining was observed, none 
of them stained weakly, 6 (26%) stained moderately, 3 (14%) stained strongly. Among 
the 35 moderately malignant cases with GS 6-7, 10 (28%) no staining was observed, 6 
(16%) stained weakly, 10 (28%) stained moderately and 10 (28%) stained strongly. Of 
the 33 highly malignant cases with GS 8-10, 4 (13%) no staining was observed, 5 (15%) 
stained weakly, 7 (21%) stained moderately and 17 (51%) stained strongly. The intensity 
of FABP6 staining in highly malignant cases was significantly higher than that in low 
malignant cases (χ2 test, p<0.00001). A significant difference was also observed on 
staining intensities between low malignant cases and moderately malignant cases (χ2 
test, P= 0.02).  When the staining intensities between the moderately malignant and the 
highly malignant cases was compared, the difference was not statistically significant (χ2 
test, p > 0.05).   
Of the 28 weakly malignant carcinoma tissues, 22 (78%) stained weakly, 6 (22%) 
stained moderately, none of them stained strongly. Among the 25 moderately malignant 
cases with GS 6-7, 7 (27%) stained weakly, 13 (53%) stained moderately and 5 (19%) 
stained strongly. Of the 33 highly malignant cases with GS 8-10, 2 (6%) stained weakly, 
20 (63%) stained moderately and 11 (31%) stained strongly. The intensity of FABP9 
staining in moderately malignant cases was significantly higher than that in low 
malignant cases (χ2 test, p<0.00001). Highly significant difference was also observed on 
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staining intensities between low malignant cases and highly malignant cases (χ2 test, 
P<0.00001).  When the staining intensities between the moderately malignant and the 
highly malignant cases were compared, the difference was not statistically significant (χ2 
test, p =0.09).   
 
3.5   Correlations with patient survival 
 
The level of FABP9 (Figure 3.9), AR index (Figure 3.10), PSA (Figure 3.11) or GS 
(Figure 3.12) and the duration of patients’ overall survival time (the length of survival 
time from initial diagnosis until death, or until data were censored) was plotted using 
Kaplan-Meier survival curves and the significance of the differences was assessed by 
Log Rank test as follows: 
 
3.5.1 Relationship between FABP9 and patient survival  
 
When the correlation between patient survival time and the FABP9 staining intensity 
was assessed (Figure 3.9), the median survival time for patients with weak staining for 
FABP9 was 60 months which was significantly longer than those patients with moderate 
(24 months) and strong (18 months) staining for FABP9, respectively. Overall, the 
increased FABP9 staining intensity was significantly correlated with reduced patient 
survival time (log-rank test, p = 0.02).  
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Figure 3. 9: Kaplan-Meier survival curves of patients with prostate cancer.                          
The cumulative survival of patients was plotted against the time in month for FABP 
expression. Different levels of FABP9 stains: group 1, weakly positive (n=28); group 2, 
moderately positive (n=38); group 3, strongly positive (n=21).   
 
 
3.5.2 Relationship between AR index and patient survival  
 
When the correlation between the patient survival time and AR index level was assessed 
(Figure 3.10), the median survival for patients with weak, moderate and strong staining 
for FABP9 was 60, 24 and 24 months respectively. The overall increase for the three 
groups in intensity of AR staining was not (but close to) significantly correlated with 
reduced patient survival time (log-rank test, p = 0.052). Although, the overall increase in 
intensity of AR staining was of borderline significance in correlation with reduced 
patient survival time, the median survival for patients with weak was significantly longer 
High (n=21) (18) 
Moderate (n=38) (24) 
Low (n=28) (60) 
Log Rank test, P=0.02 
FABP9 
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than patients with strong staining for FABP9 (log-rank test, p = 0.031). Also, significant 
difference was observed between the median survival for patients with weak was 
significantly longer than patients with moderately staining for FABP9 (log-rank test, p = 
0.041). However, the difference between patients with moderately and strong staining 
for FABP9 was not statistically significant (log-rank test, p > 0.05). 
 
 
 
 
 
 
 
Figure 3. 10: Kaplan-Meier survival curves of patients with prostate cancer.                          
The cumulative survival of patients was plotted against the time in month for AR index. 
Different AR indices: low group, <4 (n=41); moderate group, 4-6 (n=50); high group, 6-
9 (n=11). 
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3.5.3 Relationship between PSA and patient survival  
 
When the correlation between patient survival time and the blood level of PSA was 
assessed (Figure 3.11), the median survival time for patients with low (<10ng/ml) and 
high (≥10ng/ml) PSA levels were 48 and 18 months, respectively. The difference was 
not statistically significant (log-rank test, p = 0.246). The cut off used in this study was 
10ng/ml (PHE 2016b; Roddam et al. 2005). 
 
 
 
 
 
 
 
Figure 3. 11: Kaplan-Meier survival curves of patients with prostate cancer.                       
The cumulative survival of patients was plotted against the time in month for PSA 
levels. Different levels of PSA: group 1, PSA <10 ng/ml (n=38) and group 2, PSA ≥10 
ng/ml (n=64). 
 
 
 
<10 (n=56)  
≥10 (n=42)  
Log Rank test, P=0.246 
PSA 
Results 
129 | P a g e  
 
3.5.4 Relationship between GS and patient survival  
 
When the relationship between patient survival time and GS was assessed (Figure 3.12), 
the median survival time for patients with low GS (not reached) was significantly longer 
than for those patients with moderate (60 months) and high GS (12months), respectively. 
The increased GS was significantly correlated with the reduced patient’s survival time 
(log-rank test, p < 0.0001). 
 
 
 
 
 
 
 
 
Figure 3. 12: Kaplan-Meier survival curves of patients with prostate cancer.                       
The cumulative survival of patients was plotted against the time in month for GS. 
Different GS: group 1, GS ≤5 (n=17); group 2, GS 6 to 7 (n=38); group 3, GS 8 to 10 
(n=45).   
GS2-5 (n=17)  
GS 6-7 (n=38)  
GS 8-10 (n=45)  
Gleason Scores 
Log Rank test, P <0.0001 
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3.6 Correlation of FABP9 expression with levels of GS, 
AR index and PSA 
Assessment of correlation between the intensity of staining for FABP9 and AR index 
(Figure 3. 13) and PSA level (Figure 3. 14).  
3.6.1 Correlation of FABP9 and AR index 
 
Box plot analysis of the correlation between staining intensity for FABP9 and AR index 
showed that the AR index level was significantly higher in cases with strong staining for 
FABP9 than those cases with weak staining for FABP9 (Figure 3.13) (Mann-Whitney U 
test, p < 0.03). However, the differences in AR index levels either between cases with 
moderate and weak FABP9 satins (Mann-Whitney U test, p = 0.11) or between cases 
with strong and weak stains for FABP9 (Mann-Whitney U test, p = 0.084) were not 
statistically significant.  
 
 
 
 
 
Figure 3. 13: Box plot of correlation between stain intensity for FABP9 and androgen 
receptor (AR) index in 3 groups of patients with prostate cancer: weak, moderate and 
strong staining for FABP9. 
Mann-Whitney U test:  
Weak v Moderate, p = 0.11                                     
Moderate v Strong, p = 0.084                                    
Weak v Strong, p = 0.03 
B 
n=27 n=38 n=17 
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3.6.2 Correlation of FABP9 and PSA level 
 
For the correlation between the staining intensity of FABP9 and PSA level (Figure 
3.14), box plot analysis showed that the differences in PSA levels between cases with 
strong and weak stains for FABP9 (Mann-Whitney U test, p = 0.142), between strong 
and moderate stains (Mann-Whitney U test, p = 0.098) and between moderate and weak 
stains for FABP9 (Mann-Whitney U test, p = 0.812) were not significantly different.  
 
 
 
 
 
 
                                  
    
 
Figure 3. 14: Box plot of correlation between stain intensity for FABP9 and prostatic 
specific antigen (PSA) level in 3 groups of patients with prostate cancer: weak, moderate 
and strong staining for FABP9. 
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3.7 Suppression of FABP9 expression by siRNA 
 
PC3-M cells, highly malignant prostate cancer cells, express high level of FABP9. 
FABP9 mRNA in PC3-M was transiently knocked down by RNAi technique. The most 
efficient siRNA sequence was used to design double-stranded shRNA for stable 
transfection. In stable transfection, shRNAs were transfected into PC3-M cells to 
knockdown the FABP9 mRNA to assess whether suppression of FABP9 expression can 
inhibit the tumorigenicity of prostate cancer cells. 
3.7.1 Selection of most efficient siRNA for FABP9 suppression 
 
Three different target sequences within FABP9 cDNA were designed to form ds-siRNA 
constructs.  Highly-expressing PC3-M cells were transiently transfected for 48 hours 
with 3 different siRNAs. Western blots showed that levels of FABP9 expression after 
transfection were reduced (Figure 3.15A). Quantitative analysis showed that the levels 
of FABP9 in scramble control and PC3-M treated with transfection reagent alone were 
similar to that in the parental PC3-M cells. The relative levels in other three PC3-M 
transfectants with siRNA 1, 2 and 3 were 0.86±0.14, 0.75±0.35 and 0.45±0.30, 
respectively (Figure 3.15B). The most efficient suppression was achieved by siRNA-3 
(up to 60%) (Student’s t-test, p < 0.0001) in combination with 2.5µl/ml of X-
tremeGENE siRNA Transfection reagent in 24-hours incubation.  Therefore, siRNA-3 
was identified as the most effective suppresser and its sequence was used to design 
double-stranded shRNA for stable transfection.  
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Figure 3. 15: Knockdown of FABP9 mRNA in highly malignant prostate cancer cells.  
A), the effect of mRNA Knockdown on FABP9 expression in PC3-M cells. Western blot 
analysis of FABP9 expressed in PC3-M cells and cells transiently transfected with 3 
different siRNA molecules. As loading control, β-actin was detected on the same blot. 
B), relative levels of FABP9 in PC3-M after transient transfection. The level of FABP9 
in parental PC3-M was set at 1.0 and levels expressed in transiently transfectant cells 
were related to that in parental cells. Results were obtained from three different 
measurements (mean ± SD). 
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3.7.2 Establishment of stably FABP9-suppressed PC3-M cell 
lines 
 
 To establish stably suppressed FABP9 with highly malignant PC3-M cells, shRNA was 
designed using siRNA-3 as template. psiRNA-h7SKGFPzeo plasmid was doubled 
digested with two restriction enzymes HindIII and Acc651. Electrophoresis in low-
temperature melting agarose (1%) gel was performed to confirm the successful double 
cleavages (Figure 3.16). The gel containing the appropriate band was cut out, the DNA 
was extracted from the gel and ligated with a short shRNA molecule formed by 
annealing a forward and a reverse oligonucleotide. Ligation product was transformed 
into E.coli GT116 competent cells, plated onto a LB-Zeocin agar plate, and incubated 
overnight in a 37oC incubator. The control and shRNA plasmid transformation 
efficiencies were 3800 and 1500 cfu, respectively. 
 
 
 
 
 
Figure 3. 16: Digestion of psiRNA-h7SKGFPzeo plasmid.                                 
Electrophoresis was performed in Low-melting temperature agarose gel (1%) to confirm 
the successful cleavage of the plasmid DNA. Undigested psiRNA-h7SKGFPzeo plasmid 
was loaded in well 1 and digested one in well 2. The extra small band (arrow) was the 
369 bp fragment of plasmid that was replaced by shRNA in ligation process. 
1    2 
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3530 bp  
564 bp 
369 bp 
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Three single clones of transformed bacteria with FABP9-suppressed and 1 clone from 
scramble shRNAs were picked up and grown in LB medium containing 100µg/ml 
Zeocin. Then, QIAGEN plasmid mini-preparation kit was used to extract and purify 
plasmid DNAs from bacteria cells. Plasmids were double digested with Hind III and 
Acc651 restriction enzymes. Electrophoresis in low-melting temperature agarose (1%) 
gel was performed to confirm that the shRNA fragments were inserted into the vector 
(identified by the arrows) (Figure 3.17). The undigested psiRNA-h7SKGFPzeo plasmid 
in parallel with the digested sample was used as control as shown in Figure 3.17. After 
ascertain the shRNA was inserted, plasmids from three different clones (2-4) were sent 
to Beckman Coulter Genomics, UK for sequencing analysis. Sequencing analysis result 
confirmed the correct size, sequence and orientation of inserts as shown in Table 3.3. 
Plasmid from clone 4 was chosen for the subsequent stable transfection. Specificity of 
these sequences was confirmed by Genbank Blast search. 
 
 
 
 
 
 
 
 
Results 
136 | P a g e  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. 17: Confirmation of the correct DNA insertion.                                                            
Mini-preparation of DNA was made from 2 colonies harbouring FABP9-suppressed 
DNA constructs (lane 6 and 8) and 1 colony harbouring scramble-shRNA plasmids (lane 
4). DNA from each clone was double digested using HindIII and Acc651 restriction 
enzymes (lane 2, 4, 6 and 8) and an undigested plasmid DNA sample was loaded in 
parallel with the digested sample as control (lane 1, 3, 5 and 7). The smaller bands 
(identified by the arrows) represent shRNA fragments (369 bp). The bigger bands 
represent digested psiRNA-h7SKGFPzeo plasmid.  
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Forward 
 
5’NNNNANTNNTNNGTTATNAGCTTGTGCGCCGCCTGGGTACCTCGGTTAGTGAAACCGACAG
TTCAAGAGACTGTCGGTTTCACTAACCTTTTTGGAAAAGCTTCTAGACTTAATTAACCTGCAG
GCGTTACATAACTTACGGTAAATGGCCCGCCTGGCTGACCGCCCAACGACCCCCGCCCATTG
ACGTCAATAATGACGTATGTTCCCATAGTAACGCCAATAGGGACTTTCCATTGACGTCAATG
GGTGGAGTATTTACGGTAAACTGCCCACTTGGCAGTACATCAAGTGTATCATATGCCAAGTA
CGCCCCCTATTGACGTCAATGACGGTAAATGGCCCGCCTGGCATTATGCCCAGTACATGACC
TTATGGGACTTTCCTACTTGGCAGTACATCTACGTATTAGTCATCGCTATTACCATGATGATG
CGGTTTTGGCAGTACATCAATGGGCGTGGATAGCGGTTTGACTCACGGGGATTTCCAAGTCT
CCACCCCATTGACGTCAATGGGAGTTTGTTTTGACTAGTAAATCAACGGGACTTTCCAAAATG
TCGTAACAACTCCGCCCCATTGACGCAAATGGGCGGTAGGCGTGTACGGTGGGAGGTCTATA
TAAGCAGAGCTCGTTTAGTGAACCGTCAGATCAGCTTCGAGGGGCTCGCATCTCTCCTTCACG
CGCCCGCCGCCCTACCTGAGGCCGCCATCCACGCCGGTTGAGTCGCGTTCTGCCGCCTCCCGC
CTGTGGTGCCTCCTGAACTGCNNCCGCCGTCTAGGTAAGTTTAAAGCTCAGGTCGAGACCGG
GCCTTTGTCCGGCGCTCCCTTGGAGCCTAGCTAGACTCAGCCGGCTCTCCACGCTTTGCCTGA
CCCTGCTTGCTCAACTCTACGTCTTTGATTCCGTNATCTGTTCTGCGCCGTTACAGATTCCAAG
CCACCATGGGTTTCTAACGGGAGAAGAACTNTTAACTGGCAGTTGTCCCCATTCCNNGGTTG
ACCNTGANNGNTGATGTGAATGGCCNNNNAATTCCTCTGTGTCNNNGNNTAATATGGAAGG
NAANTGCAANCCTCATGGAANTCT 3’ 
 
Reverse 
5’TTANNGGNCGGNNTCGTTGGNCGGTCAGCCAGGCGGGCCATTTACCGTAAGTTATGTAACG
CCTGCAGGTTAATTAAGTCTAGAAGCTTTTCCAAAAAGGTTAGTGAAACCGACAGTCTCTTG
AACTGTCGGTTTCACTAACCGAGGTACCCAGGCGGCGCACAAGCTATATAAACCTGAAGGAA
ATCTCAACTTTACACTTAGGTCAAGTTACTTATCGTACTAGAGCTTCAGCAGGAAATTTAACT
AAAATCTAATTTAACCAGCATAGCAAATATCATTTATTCCCAAAATGCTAAAGTTTGAGATA
AACGGACTTGATTTCCGGCTGTTTTGACACTATCCAGAATGCCTTGCAGATGGGTGGGGCAT
GCTAAATACTGCAGCACTAGTATCGATTAAGAACATGACCAAAATCCCTTAACGTGAGTTTT
CGTTCCACTGAGCGTCAGACCCCGTAGAAAAGATCAAAGGATCTTCTTGAGATCCTTTTTTTC
TGCGCGTAATCTGCTGCTTGCAAACAAAAAAACCACCGCTACCAGCGGTGGTTTGTTTGCCG
GATCAAGAGCTACCAACTCTTTTTCCGAAGGTAACTGGCTTCAGCAGAGCGCAGATACCAAA
TACTGTTCTTCTAGTGTAGCCGTAGTTAGGCCACCACTTCAAGAACTCTGTAGCACCGCCTAC
ATACCTCGCTCTGCTAATCCTGTTACCAGTGGCTGCTGCCAGTGGCGATAAGTCGTGTCTTAC
CGGGTTGGACTCAAGACGATAGTTACCGGATAAGGCGCAGCGGTCGGGCTGAACGGGGGGT
TCGTGCACACAGCCCAGCTTGGAGCGAACGACCTACACCGAACTGAGATACCTACAGCGTGA
GCTATGAGAAAGCGCCACGCTTCCCGAANGGAGAAAGGCGGACAGGTATCCGGTAAGCGGC
AGGGTCGGAACAGGAGAGCGCACGAGGGAGCTTCCAGGGGGAAACGCCTGGTATCTTTATA
GTCCTGTCGGGTTTCGCCACCTCTGACTTGAGCGTCGATTTTTGTGATGCTCGTCAGGGGGGN
CGGANCCTATGGNAAAANCGCCAGCAACGCTGGCTTTTTNACGGGTTCCTGGNCCTTTNGCT
GGNCNTTTNGCTCACATGCATAAAAAAANCCCNNCCAAANCGGGNTTTNANNTTAAAANTTA
AGCCATACCAANCC 3’ 
Table 3. 3: A part of psiRNA-h7SKGFPzeo plasmid sequence map.                                                   
To confirm the correct insertion of shRNA (highlighted in red), plasmid from clone 4 
was sequenced using internal plasmid primers by Beckman Coulter Genomics, UK. 
Sequence alignment was performed using BioEdit for searching Genbank and the results 
proved that the insertion was correct. 
Results 
138 | P a g e  
 
3.7.3 Stable transfection  
 
For stable transfection, shRNAs from clone 4 were cloned into the psiRNA-
h7SKGFPzeo plasmid and were transfected into PC3-M cell line using X-tremeGENE 
HP DNA Transfection Reagent (2.5μl/ml) to knockdown FABP9 mRNA. After 48 
hours, culture medium was replaced with fresh media containing ZeocinTM (100µg/ml). 
Then, transfectant cells were transferred into 9cm cell culture plates (petri dish) until 
clones can be visualized with naked eye. Five single clones of FABP9-suppressed 
trasfectants and 2 scramble trasfectants were isolated using ring cloning method 
described in section 2.5.6.1 and grown in a 96-well plate. The clones were grown in 
normal cell culture condition for one week.  
When Western blot was used to measure the level of FABP9 from different individual 
colonies of transfectants, a single 15 kDa FABP9 band was detected and levels of 
FABP9 in scramble control PC3-M, parental PC3-M and 5 single transfectant clones are 
shown in Figure 3.18A. Further quantitative analysis showed that the level of FABP9 in 
scramble control was similar to that in the parental PC3-M cells. The relative levels of 
FABP9 in 1-5 single colonies were reduced by 15%, 25%, 43%, 50% and 91%, 
respectively (Figure 3.18B). Thus sub-lines established from clone 4 and clone 5 were 
selected as moderately (PC3M-FABP9-siM) and highly (PC3M-FABP9-siH) suppressed 
transfectant lines, respectively. To confirm that the suppression was not via FABP5, 
Western blot analysis was used to assess the effect of FABP9 mRNA knockdown on 
FABP5 expression in PC3-M cells (Figure 3.19A). Quantitative analysis showed that 
the levels of FABP5 in PC3M-FABP9-siM and PC3M-FABP9-siH were similar to that 
in the parental PC3-M cells (Figure 3.19B). 
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Figure 3. 18: Knockdown of FABP9 mRNA in highly malignant prostate cancer cells.  
A) Western blot analysis of FABP9 in control PC3-M cells and 5 different clones 
generated by transfection with the shRNA based on siRNA-3. As loading control, β-
actin was detected on the same blot. B) the relative levels of FABP9 in PC3-M 
transfected with scramble shRNA control was set at 1.0 and levels expressed in other 
transfected cell lines were obtained by comparing with the control. Results were 
obtained from three different measurements (mean ± SD). 
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Figure 3. 19: A) Western blot analysis of FABP5 in transfectants expressing reduced 
levels of FABP9. B) The relative levels of FABP5 in PC3M-FABP9-siM and PC3M-
FABP9-siH were similar to that in the parental PC3-M cells.  
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3.8 Effect of FABP9-suppression on tumour cells in 
vitro 
 
3.8.1 Effect of FABP9-suppression on cellular proliferation 
 
To identify the cell number in MTT assay, standard curve of each cell line was 
generated to correlate optical density of formazan with cell number as shown in Figure 
3.20. Proliferation assay was performed triplicate on controls and transfectants over 6 
days to test whether suppression of FABP9 can affect the growth rate of PC3-M cells. 
The result was shown in Figure 3.21. MTT proliferation assay was performed to assess 
the effect of reduced suppressed-FABP9 on the proliferation ability of PC3-M cells. The 
density of culture cells was determined by extrapolating standard curve, and 
proliferation rates of different transfectants were measured by MTT assay. Overall, 
growth rate of parental cells and tansfectants exhibited a very similar growth pattern. On 
1st and 2nd day, no significant difference was detected between parental control and 
PC3M-FABP9-siM and PC3M-FABP9-siH (Student’s test, p > 0.05). Although at day 3, 
there was a reduction in both PC3M-FABP9-siM (15566± 2016) and PC3M-FABP9-siH 
(18441 ± 2820) cells compare to parental control (21709 ± 4901), but not statistically 
significant (Student’s test, p > 0.05) (Table 3.4). On the 4th, 5th and 6th day, the number 
of PC3M-FABP9-siM and PC3M-FABP9-siH cells growth rates were not significantly 
reduced in both PC3M-FABP9-siM and PC3M-FABP9-siH cells compared to parental 
PC3-M cells (Student’s test, p > 0.05). Therefore, cell proliferation of PC3M-FABP9-
siM cells and PC3M-FABP9-siH cells were not significantly different compare to 
control cells. 
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Figure 3. 20: Standard curves of parental PC3-M and different transfectant cell lines.  
Using linear regression analysis, Standard curves were established for each cell line by 
plotting absorbance (OD at 570 nm) (Y axis) against the cell numbers (X axis). The 
curve equation and regression of each standard curve is presented in diagram. 
Table 3. 4: Cell counts of parental and transfectant PC3-M cells at the 3rd day of 
proliferation assay in 3 separate experiments. Using Student’s t-test, p values were 
obtained by comparing data from test groups to parental group. 
Cell Line Mean No. of Cells ± SD P Value 
                   
                  PC3-M 
 
21709 ± 4901 
 
…. 
 
PC3-M-FABP9-siM 
 
15566 ± 2016 
                        
                 = 0.115 
 
PC3-M-FABP9-siH 
 
18441 ± 2820 
 
 = 0.373 
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Figure 3. 21: The impact of FABP9 suppression on the proliferation rate of transfectant 
cells.                                                                                                                                                                                   
The growth rates of parental, PC3M-FABP9-siM and PC3M-FABP9-siH cells during a 
6- day experimental period. Cell count of each sample was calculated by comparing to 
serially diluted standard from standard curve. Data expressed as means + SD of three 
independent experiments. 
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3.8.2 Effect of FABP9 suppression on invasiveness of prostate 
cancer cells 
 
The effect of FABP9-supression on invasiveness of prostate cancer cells was evaluated 
by an invasion assay using BD Matrigel coated invasion chambers as shown in Figure 
3.22. The invasiveness of the transfectants was assessed in a BD BioCoatTM MatrigelTM 
Invasion Chamber (BD Biosciences, USA). After 24-hour starvation, PC3-M and 
transfectant cells at a density of 2.5x104 cells/ml were loaded into every upper 
compartment of chambers. Routine medium was loaded in the lower compartment and 
serum-free medium was used as negative control for each cell line. The chambers were 
maintained in a humidified tissue culture incubator at 37ºC, 5% CO2 (v/v). All cell lines 
were set as triplicate and assay was run in a humidified tissue culture incubator for 24 
hours. After 24-hour cells in the upper compartment were removed and washed with 
PBS. Then, the invaded cells in the lower part were fixed and stained with 2% (v/v) 
crystal violet for 10 minutes. The number of invaded cells was counted under a light 
microscope. The invaded cells were counted in nine random fields using light 
microscope at 125 × magnification (Figure 3.22A). The number of invaded cells (mean 
± SD) from scramble control, PC3M-FABP9-siM and PC3M-FABP9-siH were 43±7, 
26±4 and 15±5, respectively (Figure 3.22B). PC3M-FABP9-siM and PC3M-FABP9-siH 
were representing significant reductions by 39.5% (Student’s t-test, p = 0.008) and 
65.1% (Student’s t-test, p = 0.001), respectively as tested in BD Matrigel coated 
invasion chambers (Table 3.5). Invasiveness of PC3M-FABP9-siH was significantly 
reduced when compared with the invasiveness of PC3M-FABP9-siM cells (Student’s t-
test, p = 0.021).  
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Figure 3. 22: The effect of FABP9 suppression on invasiveness of transfectant cells.          
A) 3 panels represent the invasiveness of the control, moderately suppressed (PC3-M-
FABP9-siM) and highly suppressed (PC3-M-FABP9-siH) cells respectively. B) Number 
of invaded cells per field in invasion assay; cells were incubated in BD Matrigel coated 
invasion chambers with serum-free medium for 24 hours.  The results (mean ± SD) were 
obtained from 3 separate experiments.  
**
**
0
5
10
15
20
25
30
35
40
45
50
Scramble PC3M-FABP9-siM PC3M-FABP9-siH
N
u
m
b
er
 o
f 
in
v
a
d
ed
 c
el
ls
PC3-M-FABP9-siM PC3-M-FABP9-siH Control 
A 
B 
Results 
146 | P a g e  
 
 
Table 3. 5: Number of invaded cells (mean ± SD) produced in three separate 
experiments. Differences of invasiveness between different groups were assessed by 
Student’s t-test. p values were obtained by comparing data in test groups to control 
group. 
Cell Line Mean No. of Colonies ± 
SD 
P Value 
                   
                  PC3-M 
 
43 ± 7 
 
…. 
 
PC3-M-FABP9-siM 
 
26 ± 4 
 
0.008 
 
PC3-M-FABP9-siH 
 
15 ± 5 
 
0.001 
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3.8.3 Effect of FABP9 suppression on anchorage-independent 
growth of prostate cells 
 
To assess anchorage-independent growth of FABP9-shRNA transfectants, soft agar 
assay was performed (Figure 3.23). The assay was set in triplicate and scramble cells 
were used as control. Control cells and transfectants were grown for 4 weeks. During the 
4-week incubation, cells were feed with 200ul/well once a week. At the end of the assay, 
colonies were stained by adding 0.5ml of 2% MTT (5mg/ml). Colonies larger than 
150µm were counted using Gel Count. The result of the anchorage-independent growth 
capability of the cells were shown in Figure 3.23A. The average number of colonies 
produced by scramble, PC3M-FABP9-siM and PC3M-FABP9-siH cells were 188±6, 
138±10 and 161±9, respectively (Figure 3.23B). Colony formation of PC3M-FABP9-
siM (Student’s t-test, p = 0.3) and PC3M-FABP9-siH cells (Student’s t-test, p= 0.5) 
were not significantly different from control cells as shown in Table 3.6. 
 
Table 3. 6: Colony counts of transfected cells in at 4th week of triplicate soft agar assay. 
Differences of number of colonies between different groups were assessed by Student’s 
t-test. p values were obtained by comparing sample groups to control group data. 
Cell Line Mean No. of Colonies ± 
SD 
P Value 
                   
                  PC3-M 
 
188 ± 6 
 
…. 
 
PC3-M-FABP9-siM 
 
138 ±10 
 
0.3 
 
PC3-M-FABP9-siH 
 
161 ±9 
 
 
0.5 
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Figure 3. 23:  The impact of FABP9 silencing on the anchorage-independent growth of 
tranfectant cells.                                                                                                                                                            
A) Representative plates of soft agar colony formation with different transfectants. B) 
Colony counts of different transfectants; Results were obtained from three separate 
experiments (mean ± SE). 
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3.8.4 Effect of FABP9 suppression on cell migration  
To assess the functional effect of FABP9 knockdown on the migratory ability of cells 
with the transfectants, wound healing assay was performed and the results are shown in 
Figure 3.24. The assay was set in triplicate and scramble cells were used as control. 
Control cells and transfectant cells (PC3M-FABP9-siM and PC3M-FABP9-siH) cells 
were grown in 6-well plate until reached 75-80% confluency. Then, a wound was 
created by making a scratch, the cells on the edge of the artificial gap migrate to close 
the scratch were monitored until cell-cell contacts are observed (Figure 3.24A). At 
different time intervals, the migration rate (as reflected by width of the scratch) of 
PC3M-FABP9-siM and PC3M-FABP9-siH cells were not significantly different from 
control cells at wound closure (Student’s t-test, p > 0.05) as shown in Table 3.7. Images 
were captured at the beginning and at regular intervals to determine the cell migration 
rate. The result showed that transfectants with either PC3M-FABP9-siM or PC3M-
FABP9-siH did not exhibit any significant difference in suppressing cell migration 
ability when compared to the control in 24 hours (Figure 3.24B).  
Table 3. 7: Migration rates of transfected cells at 24 hours in wound healing assay. 
Time intervals PC3-M PC3M-FABP9-siM PC3M-FABP9-siH 
0 Hour …. …. …. 
6 Hours …. P value > 0.05 P value > 0.05 
12 Hours …. P value > 0.05 P value > 0.05 
24 Hours …. P value > 0.05 P value > 0.05 
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Figure 3. 24: The impact of FABP9 silencing on migration rate of tranfectant cells.            
A) Representative images of wound healing with control and different transfectants 
(PC3M-FABP9-siM or PC3M-FABP9-siH). B) Migration rate of different transfectants; 
Results were obtained from three separate experiments (mean ± SE).
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4 Discussion  
Prostate cancer is the most common male cancer in the developed countries and a 
worldwide male health threat (CRUK 2013). Previous studies showed that some FABPs 
were implicated in progression of several cancer types including prostate cancer and 
could be used as tumour biomarkers (Boiteux et al. 2009; Hammamieh et al. 2005; 
Ohmachi et al. 2006). FABPs are intracellular lipid-binding proteins that bind 
intracellular hydrophobic ligands such as saturated or unsaturated medium- or long-
chain fatty acids and consist of at least 12 members. Amongst the 12 members of FABP 
family proteins, FABP10 and FABP11 are restricted to fish only and not expressed in 
Homo sapiens (Agulleiro et al. 2007; Sharma et al. 2006; Venkatachalam et al. 2009). 
FABPs have been suggested to be involved in intracellular transport of lipids to 
subcellular-organelles (Furuhashi & Hotamisligil 2008). FABPs have also been 
suggested to control cancer growth through co-ordination with other fatty acid 
transporters and carcinogens (Schachtrup et al. 2004), steroids (Gao et al. 2010),  
hormones (Pinthus et al. 2007) and their derivatives (Chmurzynska 2006). FABP5 
played a crucial promoting role in tumorigenicity and metastasis of prostate cancer (Jing 
et al. 2001; Jing et al. 2000). Increased FABP5 expression in archival prostate cancer 
tissues is found to be significantly associated with a reduced patient survival time (Myers, 
von Lersner & Sang 2016), suggesting that it is a valuable prognostic factor. It was also 
involved in malignant progression of pancreatic cancer (Sinha et al. 1999). It was 
reported that the FABP5 and FABP6 were overexpressed and might play promoting 
roles in colorectal cancer (Kawaguchi et al. 2016b; Ohmachi et al. 2006). FABP1 was 
shown to play a key role in breast cancer cells and has the potential to serve as a 
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diagnostic marker (Li et al. 2007). Several studies have linked FABP3 with different 
cancer types such as embryonic cancer, breast cancer and NSCLC. It has been suggested 
that FABP4 is a useful prognostic marker for urinary bladder cancer and NSCLC. It was 
also suggested to be a therapeutic target for metastasis of prostate cancer (Uehara et al. 
2014). FABP7 was shown to be a specific biomarker for renal cell carcinomas (Teratani 
et al. 2007). In addition, increased expression of FABP7 was associated with 
proliferation and invasion of melanoma cells (Slipicevic et al. 2008).  Although 
functional characterisation work and other studies demonstrated that FABP5 and other 
FABPs may be prognostic markers and treatment targets for different cancer types, the 
potential involvement of some other FABPs in malignant progression of prostate cancer 
had not been fully investigated (Al Fayi et al. 2016). The aim of this work is to 
investigate the expression of FABP proteins in a wide range of samples, including 6 
different prostate cell lines and 135 prostate tissues, with the hypothesis that FABP 
family proteins apart from FABP5 (Bao et al. 2013; Forootan et al. 2016; Forootan et al. 
2014; Morgan et al. 2008) might be diagnostic and prognostic markers or potential 
treatment targets. 
4.1 FABP6 and FABP9 were differentially expressed at mRNA level 
 
In this study, we measured mRNA levels of the other 10 different FABPs in prostate 
epithelial cells to assess whether any of them were differentially expressed between 
benign and malignant phenotypes. The results showed that FABP4, FABP5, FABP6, 
FABP9 and FABP12 exhibited clearly higher levels in all tested malignant cell lines 
compared to their levels in the benign PNT-2 cells (Figure 3.3). Amongst differentially 
expressed FABPs, FABP4 is released from adipocytes, implicated in obesity 
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(Hotamisligil et al. 1996) and its possible involvement in the malignant progression of 
prostate cancer has been investigated previously (Uehara et al. 2014). The crucial role of 
FABP5 in promoting tumorigenicity and metastasis of prostate cancer have been 
characterized by our group. For FABP6, a marked level of FABP6 mRNA expression in 
malignant cells was observed when compared with no expression in the benign cell line 
PNT-2. For FABP9, its expression in malignant cells was 5-47 folds higher than that in 
benign cells. For FABP1, FABP2, FABP3, FABP7 and FABP8 no clear differences were 
observed and therefore they are unlikely to be involved in carcinogenesis of prostate 
cancer. FABP12 is the most recently discovered member of the FABP family, its mRNA 
level in malignant cells was 3-105 fold higher than that in benign PNT-2 cells (Figure 
3.3). This result suggested that in addition to FABP4 and FABP5, FABP6, FABP9 and 
FABP12 may involve in the malignant progression of prostate cancer. For FABP12, it 
may play an important role in prostate cancer and thus a separate investigation has been 
conducted in another project to study FABP12 by a member of our group.  In contrast to 
the extensive studies on FABP proteins in different cancer types, the possible 
involvement of FABP9 in the development of prostate cancer has not previously 
reported. First, our findings were based on preliminary data suggested overexpression of 
FABP6 and FABP9 mRNA in prostate cancer cell lines when compared with benign cell 
line. Our findings suggested that FABP6 and FABP9 may play an important role in 
progression of prostate cancer because of their correlations with malignant 
characteristics at mRNA level and were selected for further studies.  Notably, the 
measurement of mRNA of 10 FABPs in cell lines was not repeated. This might cause 
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false negative, although the positive finding was subsequently confirmed by Western 
blotting. Therefore, the future work should consider this limitation.  
 
4.2 FABP9 was overexpressed in prostate cancer cells and tissues  
 
Although FABP6 was differentially expressed at the level of its mRNA, the expression 
of FABP6 in malignant cell lines was not significantly different when compared with 
benign PNT-2 cells (Student’s t-test, p > 0.05). Moreover, its nuclear expression at the 
protein level was not significantly different between the BPH and the carcinoma tissues 
(Table 3.1). These findings suggested that the result on expression of FABP6 in prostate 
tissues obtained by immunohistological staining was similar to that by Western blot. 
However, a significant difference was observed in the intensity of FABP6 staining 
between in highly malignant cases and low malignant cases (χ2 test, p<0.00001) and 
between low malignant cases and moderately malignant cases (χ2 test, P= 0.02). The 
results of the study indicate that the higher expression of FABP6 in human prostate 
cancer correlated with the GS. Therefore, this study suggest that FABP6 can predict the 
high stage of prostate cancer and can be used as a potential prognostic marker of disease 
progression in patients with clinically organ-confined prostate cancer who undergo 
radical prostatectomy. But to what extent and at what level of accuracy the status of an 
individual patient can be predicted should be evaluated in further studies. Most FABPs 
are fatty acid transporters and are localised mainly in cytoplasm (not fixed in a specific 
site) and move in and out of cell membrane to transport fatty acids. Why FABP6 is 
localised in nucleus is not known.   
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The expression of FABP9 at the mRNA level (with a size of 365 KB) (Stejskal, 
Karpisek & Bronsky 2008), in malignant cells was 5-47 fold higher than that in benign 
cells. When Western blot was used to measure FABP9 protein, its expression was high 
in highly malignant cell lines PC-3 and PC3-M, whereas its expression in the benign 
PNT-2 and low-malignant cells was not detectable (Figure 3.5). This result 
demonstrated that elevated levels of FABP9 is correlated with increased malignant 
characteristics, indicating that FABP9 might play an important role in progression and 
development of prostate cancer. Using immunohistological staining, it was found that 
the staining intensity of FABP9 was significantly higher in carcinomas than in BPH. The 
result also showed that the overall increase in FABP9 was significantly associated with 
GS (χ2 test, p < 0.05; Table 3.2), suggesting that the increased FABP9 stain can reflect 
the increased degree of malignancy, according to GS. These findings were consistent 
with PCR and Western blot results which all were in favour of FABP9 overexpression in 
prostate cancer cells and this is why this work was focused on FABP9.  
Immunohistological staining showed that FABP9 protein within prostate cells was 
localised predominantly in the cytoplasm, as what most of the FABPs do in other cancer 
cells such as FABP5 in prostate cancer tissue (Morgan et al. 2008). Also, 
immunostaining for FABP4 in prostate cancer tissue was mainly detected in the 
cytoplasm (Uehara et al. 2014). However, it has been reported that the localization of 
FABPs is different amongst different cancer type. In colorectal cancer, FABP1 was 
localized in both nucleus and cytoplasm (Lawrie et al. 2004).  Moreover, FABP7 was 
expressed in melanomas with a cytoplasmic and/or nuclear localization (Slipicevic et al. 
2008).  
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Since the combined GS is the most commonly used parameter to stratify the stage of 
prostate cancer, the fact that the increased FABP9 level is significantly associated with 
the increased GS suggests that FABP9 expression may be a useful prognostic factor. 
FABP9 is poorly understood protein and no previous study has address its role in human 
disease such as cancer. This work was the first study that directly addressing the 
involvement of FABP9 in cancer disease.   
4.3 Poor patient survival was correlated with increased expression 
of FABP9 and GS  
 
The lack of reliable biomarkers is a major problem to predict patient survival, the 
aggressiveness or potential therapeutic response of prostate cancer patients. Further 
assessment was made on the relationship between AR, PSA, GS or FABP9 expression 
and the duration of patient survival time. Assessment of the correlation between PSA 
and the length of patient survival showed no significant difference according to log-rank 
test and (p = 0.246) (Figure 3.11). Although PSA is the most common marker for 
prostate cancer, our finding is in line with the previous studies in which PSA is 
suggested to be unreliable biomarker.  
Results in this work suggested that the increase in staining intensity of AR was of 
borderline significance in correlation with reduced patient survival time (log-rank test, p 
= 0.052) (Figure 3.10). Hence, AR and PSA are not significant prognostic markers in 
our group of patients, likely because the number of cases was relatively small.  
Current results showed that reduced overall patient survival time was significantly 
associated with increased GS (log-rank test, p < 0.0001; Figure 3.12). The result also 
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showed that the increase in FABP9 was significantly correlated with reduced overall 
patient survival time (log-rank test, p < 0.02; Figure 3.9). The median survival for 
patients with weak staining for FABP9 was 60 months which was significantly 2.5- and 
3.3- times longer than those of the patients with moderate (24 months) and strong (18 
months) stains for FABP9, respectively.  
These findings suggest that increased level of FABP9 expression is significantly 
correlated with the poor prognosis in terms of patient’s survival time, similar to the 
prognosis made according to GS. Thus, FABP9 may be an alternative biomarker for 
reduced cellular differentiation and a reliable prognostic marker to predict patient 
survival.  
Both PSA and AR index (a parameter used to measure the staining intensity of AR 
(Pertschuk et al. 1995)) are used as biomarkers for prostate cancer. AR plays a key role 
in carcinogenesis of prostate cancer. Some previous studies showed that AR expression 
is correlated with the malignant progression of prostate cancer and with the reduced 
patient survival time. But, there was also evidence suggested that overexpression of AR 
is not correlated with reduced patient survival (Karantanos, Corn & Thompson 2013; 
Lee & Chang 2003; Marques et al. 2010). The expression of ARs throughout the 
progression of the prostate cancer remain controversial which might be because of 
variable response to endocrine therapy (Lee & Chang 2003). Therefore, AR expression 
may not always associate with prostate cancer development. The results in this study 
showed that the AR index is only of borderline significance in its association with 
reduced patient survival time (log-rank test, p = 0.052; Figure 3.10).  
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PSA is a glycoprotein belongs to a family so-called kallikrein and produced by the 
epithelial cells of prostate gland. In prostate cancer, the basal cell layer was disrupted, 
allowing PSA to leak into blood leading to elevated levels of circulating PSA. Hence, 
PSA becomes the most commonly used biological marker for prostate cancer. Although 
the widespread screening for PSA did lead to a degree of decline in mortality rates in 
some countries, many prostate cancer cases were not picked up by PSA screening in 
other countries. Several separate studies even suggested that PSA screening had only 
very limited or even no survival benefits, but it does not have the ability to discriminate 
between BPH and malignant lesions (Atan & Güzel 2013; Atan et al. 1996). The result 
in this study agreed with previous studies that correlation between PSA level and 
patients’ survival time was not significantly correlated (log-rank test, p = 0.246; Figure 
3.11). Therefore, neither PSA nor AR index level were reliable prognostic markers for 
prostate cancer.  
4.4 Increased expression of FABP9 was correlated with GS and AR  
When the expression of FABP9 was correlated with patient’s combined GS, the level of 
FABP9 was significantly higher in cases with high GS than in those cases with low GS 
(Mann-Whitney U test, p < 0.001). The staining intensity for FABP9 in cases with 
moderate GS (6 to 7) was significantly higher than that in cases with low GS (Mann-
Whitney U test, p = 0.007). We suggest that expression status of FABP9 was strongly 
correlated with GS and the state of tumor differentiation and then the expression of 
FABP9 can be used to predict patient outcomes and disease relapse.  
When the correlation between FABP9 expression and AR index was assessed, the level 
of the AR index was significantly higher in cases with strong FABP9 expression than in 
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cases with weak expression of FABP9 (Mann-Whitney U test, p = 0.03; Figure 3.12). In 
contrast, when FABP9 expression and PSA level was assessed, the differences in patient 
PSA level were neither significant between strong and weak FABP9 staining (Mann-
Whitney U test, p = 0.142) nor between strong and moderate FABP9 staining (Mann-
Whitney U test, p = 0.098) (Figure 3.14). This result showed that there was no 
correlation between FABP9 levels and PSA levels in blood, and suggested that PSA did 
not reflect the degree of malignancy of the carcinomas.  
Like some other previous studies, this work raised questions as to the real value of using 
PSA as a biomarker for prostate cancer.  The real benefit of the widespread use of 
screening for PSA is still a matter of debate (Kim & Andriole 2015; Schröder et al. 2009; 
Stavridis et al. 2010). It is confirmed that only 30% of patients with an abnormal PSA 
value were finally diagnosed with prostate cancer, leading to both an over-biopsy for 
diagnosis and an over-treatment of low-risk patients (Schröder et al. 2009). Conversely, 
low serum PSA levels have been detected in patients with advanced metastatic prostate 
cancer (Lee et al. 2010). 
Identification of novel biomarkers that can distinguish between the benign and the 
malignant nature of each case and can predict the severity of malignancy may provide a 
new way of disease stratification for prostate cancer and hence reduce unnecessary 
biopsies (a very invasive procedure) and nonessential treatments. The results in this 
study suggest that the nature of the patient case and the degree of malignancy are 
reflected by the level of FABP9 in the primary tumors. The results also suggest that 
FABP9 is a valuable prognostic marker to predict the outcomes of prostate cancer 
patients. Male-specific FABP9 protein, because only expressed in the testis, has several 
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important physiological roles in sperm development; including attachment of the 
acrosome to the sperm nucleus during fertilization and spermatogenesis (Kido & Namiki 
2000; Oko & Morales 1994; Smathers & Petersen 2011).  
 
4.5  Suppression of FABP9 reduced proliferation and invasiveness of 
prostate cancer cells  
 
As an initial step towards understanding the biological role of FABP9 in prostate cancer 
events, we assessed whether FABP9 regulates the proliferation, tumorigenicity, invasion 
and migration of prostate cancer cells. This part of study was performed to test the effect 
of suppressing expression of FABP9 protein on these cellular characteristics using 
highly malignant cell line. Knockdown of FABP9 mRNA was performed via RNAi in 
highly-expressing PC3-M cells to establish highly- and moderately-suppressed 
transfectant cell lines, named PC3M-FABP9-siH and PC3M-FABP9-siM, respectively. 
For PC3M-FABP9-siH cells, whose level of FABP9 was reduced by 91%, was reduced 
by 2.8- fold. In contrast that from PC3M-FABP9-siM, whose level of FABP9 was 
reduced by only 50%, was reduced by 1.6-fold. This reduction is not achieved by 
changing the level of FABP5 (Figure 3.19); as it has been reported by our group that 
FABP5 regulates the proliferation, tumorigenicity, invasion and migration of prostate 
cancer cells (Bao et al. 2013). The effect of FABP9-supression on growth rate, colony 
counts, invasiveness and migration rate was evaluated by proliferation assay, soft agar 
assay invasion assay and cell migration assay, respectively. Soft agar assay showed no 
significant colony counts (Figure 3.23) in transfectants compared to parental control. 
There was a clear reduction on growth rate of transfectants compared to parental control 
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at day 3 as shown in Figure 3.21, but not statistically significant. Knockdown of FABP9 
significantly reduced the number of cells invading through the Matrigel-coated 
membrane (Figure 3.22). FABP9 knockdown did not have significant effect on the 
migratory abilities of prostate cancer cells. The cell migration assay only assesses the 
simple migratory abilities of cancer cells because it lacks the extracellular matrix barrier. 
Whereas, invasion assay assesses the abilities to invade and degrade a Matrigel matrix 
that mimics the in vivo matrix barrier. Thus the reduced level of expression of FABP9 is 
closely related to the reduced invasive ability of the highly-malignant prostate cancer 
cells. This result suggests that FABP9 may play an important role in malignant 
progression of prostate cancer cells by promoting cellular invasion. 
5  Conclusion 
Based on the results obtained from this work, we can make several conclusions which 
can be summarised as following: 
1- FABP4, FABP5, FABP6, FABP9 and FABP12 exhibited clearly higher levels in 
all tested malignant cell lines compared to their levels in the benign PNT-2 cells. 
For the rest of the FABPs, no clear differences were observed and therefore they 
are unlikely to be involved in carcinogenesis of prostate cancer. 
2- The expression of FABP6 at protein level between benign and malignant cell lines 
and tissues was not significantly different, it is unlikely to be related to prostate 
cancer. 
3- Overexpression of FABP9 in highly malignant prostate cancer cell lines, 
suggesting that FABP9 is correlated with increased malignant characteristics, 
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indicating that FABP9 might play an important role in progression and 
development of prostate cancer. 
4- Increased FABP9 staining in prostate tissues was significantly correlated with the 
increased degree of malignancy, as reflected by the increased GS. 
5- Increased level of FABP9 expression is significantly correlated with the poor 
prognosis in terms of patient’s survival time, similar to the prognosis made 
according to GS. Thus, FABP9 may be an alternative biomarker for reduced 
cellular differentiation and a reliable prognostic marker to predict patient survival. 
6- The level of the AR index was significantly higher in cases with strong FABP9 
staining than in cases with weak expression of FABP9. 
7- The reduced level of expression of FABP9 is closely related to the reduced 
invasive ability of the highly-malignant prostate cancer cells. This result suggests 
that FABP9 may play an important role in malignant progression of prostate 
cancer cells by promoting cellular invasion. 
Thus, FABP9 is a more reliable prognostic marker than PSA to predict the outcome of 
prostate cancer patients and it may play an important role in the invasion of prostate 
cancer cells.   
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6 Future work 
To fully establish this study following further studies are needed: 
 FABP6 and FABP9 have the potential to be used as prognostic or diagnostic 
markers for prostate cancer and are promising due to its specificity for the 
disease in tissue. However, tissue is unsuitable as substrate for biomarker testing 
because of its invasiveness and expensiveness. Therefore, testing of cancer-
related biomarkers in body fluids such as serum, urine or semen that can be 
obtained in a non-invasive manner seems a suitable alternative tool. Because of 
the ease of collection, and the fact that prostate cells are directly released into the 
urethra through prostatic ducts after DRE, urine has become the future for non-
invasive biomarker testing.  
 Investigating the relationship between mRNA and protein expressions of FABP9 
and other candidate FABPs in patient tissues using qPCR-based test to find out if 
the former can replace the latter as a predictive biomarker in prostate cancer.   
 Investigating the interrelationship among FABP4, FABP5 and FABP9 (may be 
FABP12) in predicting clinical outcomes of prostate cancer, to find out whether 
these FABPs are dependent or independent on each other to predict patient 
survival time. 
  More in-vivo studies are needed to assess the ability of FABP9 to promote 
the proliferation and invasion abilities of prostate cancer cells and the possibility 
of using it as a treatment target.  
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Figure 4. 1: Project summary and findings.
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8 Appendix A:  
8.1  Equipment 
 
BD BioCoatTM Growth Factor Reduced (GFR) MatrigelTM Invasion Chamber Carbon 
steel  
BD Biosciences, USA  
…………………………………………………………………………………………… 
CO2 incubator Model TC2323  
Borolabs, Basingstoke, UK  
…………………………………………………………………………………………..... 
Cell culture filter cap flasks  
Cell culture plates  
Cryogenic vial  
Nunc, Denmark  
…………………………………………………………………………………………….. 
Coverslip (20×40mm)  
Shandon, UK  
…………………………………………………………………………………………….. 
Carbon steel surgical blades  
Swann-Morton, Sheffeild, UK  
…………………………………………………………………………………………..... 
Cryobox DNA  
Nalgene, UK 
…………………………………………………………………………………………..... 
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Falcon 2059 tube  
Becton Dikinson, USA  
…………………………………………………………………………………………….. 
Gel electrophoresis rig  
Bio-Rad, Hemel, UK  
…………………………………………………………………………………………..... 
Gel drier  
Flowgen, Nottingham, UK  
…………………………………………………………………………………………..... 
GelCount  
OXFORD OPTRONIX, Oxford, UK 
…………………………………………………………………………………………..... 
Haemocytometer slide 
Weber scientific International, NJ, USA  
…………………………………………………………………………………………...... 
 Hot plate (Ori-Block 08-3)  
Techne, England, UK  
…………………………………………………………………………………………..... 
Haemocytometer  
SLS Ltd., Nottingham, UK  
…………………………………………………………………………………………….. 
Immobilon, Transfer membrane  
Millipore, UK  
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…………………………………………………………………………………………..... 
Light microscope  
Leitz Labovert, Luton, UK  
…………………………………………………………………………………………..... 
Microtome HM355  
Microm, Oxford, UK  
…………………………………………………………………………………………..... 
Magnificent stirrer  
SLS Ltd., Nottingham, UK  
…………………………………………………………………………………………….. 
Microtubes  
Starlab, Milton Keynes, UK  
…………………………………………………………………………………………….. 
Microslide  
Surgipath, UK 
…………………………………………………………………………………………..... 
Multiskan MS (plate reader)  
Labsystem, Finland  
…………………………………………………………………………………………….. 
Microcentrifuge  
Beckman coulter, UK 
…………………………………………………………………………………………..... 
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Needle  
BD Microlance 3, Ireland  
…………………………………………………………………………………………..... 
NanoDrop spectrophotometer  
Labtech International, Ringmer, UK  
…………………………………………………………………………………………….. 
Portable Lab Scale  
AccuWeigh, WA, USA  
…………………………………………………………………………………………..... 
Pipette tips  
Qiagen tip  
QIA Shredder spin column  
QIAGEN, Crawley, UK 
…………………………………………………………………………………………….. 
Syringes  
BD Microlance 3, Ireland  
…………………………………………………………………………………………….. 
Sirius Luminometer  
Berthold detection system, Germany 
…………………………………………………………………………………………..... 
Spectrophotometer  
BioTec, Brigend, UK  
…………………………………………………………………………………………..... 
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Superior Adhesive slide  
Leica, Germany  
…………………………………………………………………………………………….. 
Sequenza slide rack  
Shandon, UK  
…………………………………………………………………………………………..... 
Tissue cassette  
Surgipath, UK  
…………………………………………………………………………………………….. 
Thermal cycler (Peltier Thermal Cycler PTC-200)  
GMI, MJ Research, MN, USA  
…………………………………………………………………………………………..... 
Tissue culture pipettes (5-50 ml)  
Generier bio-one, UK  
…………………………………………………………………………………………..... 
Universal tube  
Generier bio-one, UK  
…………………………………………………………………………………………..... 
Water bath  
Grant Instruments, UK  
…………………………………………………………………………………………..... 
Whatman filter paper  
Whatman, England, UK   
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8.2  Reagents Supplier  
 
8.2.1 Reagents for cell culture  
 
DMSO  
 
 
Sigma-Aldrich, Germany  
Foetal calf serum  Biosera, East Sussex, UK  
L-Glutamine  Lonza, Belgium  
Opti-MEM I medium  Gibco, Invitrogen, Paisley, UK  
Penicillin/ Streptomycin  Lonza, Belgium  
Phosphate buffered saline (tablet)  Gibco, Invitrogen, Paisley, UK  
RPMI 1640  PAA, Pasching, Austria  
Sodium pyruvate  Sigma, USA  
Trypsin  Gibco, Invitrogen, Paisley, UK  
Versene  Gibco, Invitrogen, Paisley, UK  
X-tremeGENE HP DNA Transfection 
Reagent  
Roche, Germany  
X-tremeGENE siRNA Transfection 
Reagent  
Roche, Germany  
Zeocin  Invitrogen, CA, USA  
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8.2.2 Reagents for Western blot  
 
β-mercaptoethanol  
 
Sigma, USA  
Ammonium persulfate (APS)  Sigma, USA  
Bradford reagent  Sigma, USA  
Bromophenol blue  Sigma, USA  
CelLytic-M  Sigma, USA  
Coomassie brilliant blue  Bio-Rad GmbH, Munchen, Germany  
ECL detection kit  GE Healthcare, Buckinghamshire, UK  
Glycine  Melford, UK  
Kodak Developer  Sigma, USA  
Kodak film  GE Healthcare, Buckinghamshire, UK  
Kodak Fixer  Sigma, USA  
Methanol  Fisher scientific, Loughborough, UK  
 
8.2.3 Reagents for IHC  
 
Acetone  
 
 
Sigma, USA  
DPX  Bios, Lancashire, UK  
EDTA  Sigma, USA  
EnVisionTM FLEX/DAB+ 
Chromogen  
DakoCytomation, Ely, UK  
EnVisionTM FLEX/HRP  DakoCytomation, Ely, UK  
Ethanol (IMS)  GENTA, Tockwith, UK  
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Formaldehyde  Sigma, USA  
Haematoxylin  Sigma, USA  
Hydrogen peroxide 30% (w/w)  BDH, England, UK  
Linker (Anti-gout IgG) (AI 5000)  Vector, USA  
Scott’s tap water  Sigma, USA  
Sodium citrate  Sigma, USA  
Sodium chloride  Melford, UK  
Tris base ultrapure  Melford, UK  
Tween-20  Sigma-Aldrich, Germany  
Xylene  GENTA, Tockwith, UK  
 
8.2.4 Reagents for RT-PCR  
 
dNTPs  
 
 
Thermo scientific, UK  
DTT  Invitrogen, Paisley, UK  
Oligo (dT)20  Agilent Technologies, CA, USA  
PCR primers  Invitrogen, Paisley, UK  
Platinum ®PCR SuperMix High Fidelity  Invitrogen, Paisley, UK  
 
8.2.5 Reagents for general 
molecular biology  
 
Ampicillin  
 
 
Sigma, USA  
Absolute ethanol  BDH, England, UK  
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Agarose  Genflow, Fradley, UK  
DNA marker III  Roche, England, UK  
DNA marker XIV  Roche, England, UK  
E. coli GT116 cell  InvivoGen, USA  
Glucose  Sigma, USA  
Glycerol  Sigma, USA  
Isopropanol  BDH, England, UK  
LB agar  Sigma, USA  
LB broth  Sigma, USA  
Magnesium chloride  Sigma, USA  
Magnesium sulphate  Sigma, USA  
MOPS  Sigma, USA  
psiRNA-h7SKGFPzeo plasmid  InvivoGen, USA  
QIAGEN Plasmid midi-preparation kit  QIAGEN, CA, USA  
QIAGEN Plasmid mini-preparation kit  QIAGEN, CA, USA  
Restriction enzymes  New England BioLabs, MA, USA  
Restriction enzymes buffers  New England BioLabs, MA, USA  
Safe View (Nucleic Acid Stain)  NBS Biological, Cambridgeshire, UK  
Tryptone  Sigma, USA  
Wizard® DNA Clean-Up System  Promega, WI, USA  
Yeast extract  Fisher scientific, Loughborough, UK  
Zeocin  Invitrogen, CA, USA  
 
Appendix 
204 | P a g e  
 
8.2.6 Reagents for cell 
proliferation assay  
 
MTT  
 
 
 
Sigma, USA  
 
8.2.7 Reagents for cell 
invasion assay  
 
Crystal violet  
 
 
Sigma, USA  
 
8.2.8 Reagents for soft agar 
assay 
 
Low melting point agarose  
 
 
Genflow, Fradley, UK  
MTT  Sigma, USA  
 
 
8.3 BUFFERS  
 
8.3.1 Cell Culture 
  
Routine cell culture medium  
RPMI medium 1640……….500ml  
Foetal calf serum…………. 10% (v/v)  
Pen-Strep (5000 U/ml) …... 5ml  
L-Glutamine (20mM) …… 5ml  
Sodium pyruvate (100mM) ... 5ml 
Selective medium  
Routine medium with ZeocinTM… (100μg/ml) 
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Trypsin/EDTA solution (T/E) (2.5%)  
1× Versene……………. 100ml  
Trypsin…………………2.5ml 
MTT solution (5mg/ml)  
MTT…………………….50mg  
PBS……………………...10ml  
PBS  
PBS………………………1 tablet  
dH2O…………………… 500ml  
Autoclaved 
 
8.3.2 Western Blot  
 
1M Tris pH 6.8  
Tris base………………...12.1gr  
dH2O…………………. 100ml  
pH adjusted with HCl  
10% (w/v) SDS solution  
Sodium Dodecyl Sulfate…10gr  
dH2O…………………100ml  
10% (w/v) APS solution  
Ammonium persulfate...100mg  
dH2O…………………...1ml  
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2× SDS-PAGE sample loading buffer (SLB)  
1M Tris-HCl (pH 6.8) …2.5ml  
Glycerol 40% (v/v) …... 4ml  
Bromophenol blue 0.5% (w/v) …...0.8ml  
SDS 10%........................2ml  
β-mercaptoethanol…….0.5ml  
dH2O…………………. 4.7ml   
5× SDS-PAGE sample loading buffer (SLB)  
1M Tris-HCl (pH 6.8) …1.25ml  
Glycerol 40% (v/v) …….15ml  
Bromophenol blue 0.5% (w/v) …2.5ml  
SDS 10% ……………………….5ml  
β-mercaptoethanol …………….1.25ml  
Transfer buffer (pH 8.3)  
Glycine ……………………….14.4g (192mM)  
Methanol …………………… 20% (v/v)  
Tris base ……………………. 3.03g (25mM)  
dH2O ………………………. up to 1Lit  
pH adjusted with HCl  
10× TBS buffer (pH 7.6)  
Sodium chloride …………... 87.66gr (1500mM)  
Tris base …………………... 60.58gr (500mM)  
dH2O ……………………… up to 1 Lit  
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pH adjusted with HCl  
Autoclaved  
1×TBS-Tween 1%  
10× TBS buffer …………… 100ml  
Tween 20 …………………. 1ml  
dH2O ………………….…. up to 1 Lit  
TBS-T-milk 5% (protoblock)  
Dried milk ………………. 5gr  
1×TBS-T ………………... 100ml 
 
8.3.3 Immunohistochemistry  
 
Hydrogen peroxide-Methanol solution  
Hydrogen peroxide 30% (w/w) ….12ml  
Methanol ………………………... 400ml  
 
Sodium citrate buffer (10mM)  
Tris sodium citrate……………. 29.41gr  
dH2O …………………………. up to 10 Lit  
pH 6; adjusted with HCl  
EDTA buffer (pH 7)  
EDTA …………………………37.2gr  
Sodium hydroxide …………… 3.2gr  
dH2O …………………………. up to 10 Lit  
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TBS-Tween 5%  
Sodium chloride ……………... 87.66gr (1500mM)  
Tris base ……………………... 60.58gr (500mM)  
Tween 20 ……………………. 5ml  
dH2O …………………………. up to 10 Lit  
pH adjusted with HCl  
Acid/alcohol 1%  
HCl …………………………… 20ml  
IMS …………………………... 1400ml  
dH2O …………………………. 60ml  
Scott’s tap water  
MgSO4…………………….…. 20gr  
NaHCO3……………………... 3.5gr  
dH2O ………………………... up to 1 Lit 
 
8.3.4 Molecular Biology 
  
LB medium  
LB broth ……………………20gr  
dH2O ……………………… 1 Lit  
Autoclaved  
LB agar  
LB agar …………………….35gr  
dH2O ……………………… 1 Lit  
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Autoclaved  
RF 1 buffer (pH 5.8)  
KClb ……………………… 7.456gr (100mM)  
MgCl2.4H2O ……………… 9.9gr (50mM)  
K-acetate …………………. 2.94gr (30mM)  
CaCl2 ………………….…. 1.5gr (10mM)  
Glycerol (v/v) ……………. 150ml (15%)  
dH2O ……………………... up to 1 Lit  
Adjust the pH and sterilized by filtration  
RF 2 buffer (pH 6.8)  
MOPS ……………………. 2.1gr (10mM)  
KCl ………………………. 0.745gr (10mM)  
CaCl2 ……………………. 11gr (75mM)  
Glycerol (v/v) ………….... 150ml (15%)  
dH2O ……………………. up to 1 Lit  
Adjust the pH and sterilized by autoclave  
Glucose 20%  
Glucose …………………. 20gr  
dH2O …………………… 10ml  
Sterilized by filtration 
Magnesium salt solution (2M)  
MgCl2 …………………… 2.033gr (1M)  
MgSO4 …………………... 2.465gr (1M)  
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dH2O ……………………. 10ml  
Sterilized by filtration  
SOB medium (pH 7)  
Tryptone ………………… 20gr  
Yeast extracts …………… 5gr  
NaCl.………………….…. 0.5gr  
KCl ……………………… 0.186gr  
dH2O ……………………. up to 1 Lit  
Adjust the pH and sterilized by autoclave  
SOC medium  
SOB medium …………… 4.850ml  
Mg2+ salt solution (2M) … 50μl  
Glucose 20% ……………. 150μl  
Stock medium for bacteria  
Glycerol ………………… 5ml  
LB medium ……………. 4ml  
Bacteria culture ………... 3ml  
10× TBE stock solution  
Tris base ………………. 108gr (890mM)  
Boric acid ……………... 55gr (890mM)  
EDTA 0.5M, pH 8 ……. 40ml (20mM)  
dH2O …………………. up to 1 Lit  
Adjust the pH and sterilized by autoclave  
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50× TBE stock solution  
Tris base ……………… 242gr  
Glacial Acetic Acid …... 57.1gr  
EDTA 0.5M, pH 8 …… 100ml  
dH2O …………………. up to 1 Lit  
Adjust the pH and sterilized by autoclave  
TE buffer (pH 7.6)  
Tris-HCl ……………… 1.21gr (10mM)  
EDTA ………………… 0.3722gr (1mM)  
dH2O …………………. up to 1 Lit  
Adjust the pH and sterilized by autoclave  
6×DNA loading buffer  
Bromophenol blue 0.5% …. 0.5ml  
Xylene cyanol FF …………0.5ml  
Glycerol in sterile dH2O (60%) ... 1ml 
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